key: cord-0036355-201vz404
authors: Braddock, Martin
title: Methods for Testing Immunological Factors
date: 2015-07-28
journal: Drug Discovery and Evaluation: Pharmacological Assays
DOI: 10.1007/978-3-319-05392-9_45
sha: f64f08da9fe3754e107814ebd572339f2933c3b2
doc_id: 36355
cord_uid: 201vz404

Hypersensitivity reactions can be elicited by various factors: either immunologically induced, i.e., allergic reactions to natural or synthetic compounds mediated by IgE, or non-immunologically induced, i.e., activation of mediator release from cells through direct contact, without the induction of, or the mediation through immune responses. Mediators responsible for hypersensitivity reactions are released from mast cells. An important preformed mediator of allergic reactions found in these cells is histamine. Specific allergens or the calcium ionophore 48/80 induce release of histamine from mast cells. The histamine concentration can be determined with the o-phthalaldehyde reaction.

In Vitro Methods

Purpose and Rationale Hypersensitivity reactions can be elicited by various factors: either immunologically induced, i.e., allergic reactions to natural or synthetic compounds mediated by IgE, or nonimmunologically induced, i.e., activation of mediator release from cells through direct contact, without the induction of, or the mediation through immune responses. Mediators responsible for hypersensitivity reactions are released from mast cells. An important preformed mediator of allergic reactions found in these cells is histamine. Specific allergens or the calcium ionophore 48/80 induce release of histamine from mast cells. The histamine concentration can be determined with the o-phthalaldehyde reaction.

Wistar rats are decapitated and exsanguinated. Fifty ml of Hank's balanced salt solution (HBSS) is injected into the peritoneal cavity, and following massage of the body, the abdominal wall is opened. The fluid containing peritoneal cells is collected in a centrifuge tube and centrifuged at 2,000 rpm. The cells are resuspended in HBSS. Then the cell suspension is brought to a final concentration of 10 5 mast cells/100 μl.

Test Compound Administration and Induction of Histamine Release 1 ml test drug (concentration range between 10 À4 and 10 À8 Mol) is added to the mast cell suspension (10 5 cells/100 ml) and the mixture is incubated at 37 C for 15 min. The cells are made up to a volume of 3 ml with HBSS, an equal volume of calcium ionophore (10 À6 g/ml), compound 48/80, or specific allergen is added. The suspension is incubated at 37 C for 30 min followed by centrifugation at 2,500 rpm.

The Following Control Solutions Are Needed • Spontaneous histamine release: contains only mast cells and solutions used to determine the baseline • Histamine release: contains mast cells and solutions and calcium ionophore (10 À6 g/ml) • Test compound control: contains solutions and test compound to test the compound for native fluorescence • Solution control: contains only solutions used in the test to determine the baseline

One ml of the top layer is transferred to a tube containing 300 mg NaCl and 1.25 ml butanol. The sample is alkalized to extract the histamine into butanol by adding 1 ml 3 N NaOH. Following mechanical shaking, the sample is centrifuged for 5 min. One ml of the top layer (butanol) is pipetted into a 5-ml tube containing 2 ml of n-heptane and 0.4 ml of 0.12 N HCl. The tube is mixed by inverting it several times. Following separation into aqueous and organic phases, 0.5 ml of the aqueous phase is transferred to another tube.

To each sample, 100 μl 1 N NaOH is added under constant stirring immediately followed by administration of 100 μl 0.2 % o-phthalaldehyde solution. After 2 min, the o-phthalaldehyde complexing reaction is stopped by addition of 50 μl 3 N HCl.

The total sample is transferred to an autosampler vial, and the histamine concentration is determined by a fluorescence detector (using excitation and emission wave lengths of 350 and 450 nm, respectively).

Percent histamine release (hist. rel.) can be expressed by the following formula:

Sample hist: rel: À Spontaneous hist: rel: 100% hist: rel: À Spontaneous hist: rel: Â 100

The statistical evaluation is carried out using the Student's t-test (comparison of 100 % control to experimental group).

Critical Assessment of the Method Disodium cromoglycate has been reported to inhibit the release of histamine and the degranulation of rat mast cells (Orr and Cox 1969; Orr et al. 1971; Johnson and Bach 1975; Church and Young 1983) . However, this effect of disodium cromoglycate and its analogues does not parallel the clinical efficacy (Kay et al. 1987) . Johnston et al. (1978) studied the increased superoxide anion production by immunologically activated and chemically elicited macrophages. Flint et al. (1985) found a significant inhibition of histamine release by disodium cromoglycate in human mast cells recovered by bronchoalveolar lavage. Ali et al. (1985) investigated the histamine release from rat peritoneal mast cells, human basophil and neutrophil leukocytes, and mast cells from mesentery of the lung and heart of rats and guinea pigs by the skin irritating constituents thapsigargin and thapsigargicin from the resin of the umbelliferous plant Thapsia garganica.

Eady (1986) studied the reactivity of mast cells in bronchoalveolar lavage fluid of macaques repeatedly infected with Ascaris suum. Wells et al. (1986) compared release of histamine, LTC 4 , and PGD 2 from primate bronchoalveolar mast cells with that of rat peritoneal mast cells.

The release of β-hexosaminidase from mouse or rat bone marrow-derived mast cells and from rat peritoneal mast cells was studied by Broide et al. (1986) .

Cultured lymphocytes can be stimulated to a proliferative response and to DNA synthesis by various mitogens. Measurement of DNA synthesis can be accomplished by pulse-labeling the culture with tritiated thymidine ( 3 H-thymidine), a nucleoside which is incorporated into the newly synthesized DNA. Immunomodulating properties can be detected either by pretreatment of the animals in vivo or by adding the test drug to the cultured lymphocytes.

Mice of NMRI strain weighing 18-20 g or rats of Lewis strain weighing 180-200 g are used.

Sheep red blood cell (SRBC)-specific antigen and/or the following mitogens:

• Lipopolysaccharide 10-0.1 μg/ml. • Dextran sulfate 30-7.5 μg/ml. • Phytohaemagglutinin 0.5-0.12 % stock solution. • Concanavalin A 0.5-0.12 μg/ml. • As standards, levamisole, cyclosporine A, prednisolone, or leflunomide are used.

Animals receive the test compound once a day for 5 days. Thereafter, they are sacrificed, spleens are removed, and a single cell suspension of 5 Â 10 6 cells/ml is prepared. Mitogens are titrated (four replicates/group) in 0.1 ml/well and 0.1 ml of the cell suspension is added. Plates are incubated at 37 C in 5 % CO 2 in air for 48-60 h and for another 8 h after addition of 0.25 μC 3 H-thymidine per well. Cells are harvested on glass fiber filters, and after drying the degree of radioactivity is determined using a β-counter.

Animals are sacrificed and their spleens removed. A single cell suspension of 10 7 cells/ml is prepared and 0.05 ml placed in each microtiter well (four replicates/group). Then the test compound (four times concentrated) is added in 0.05 ml. At last 0.1 ml of the double concentrated mitogen is added. Plates are incubated and processed as described above.

Evaluation Stimulation index = proliferation ratio according to positive control, either with or without mean

Purpose and Rationale Activation and/or proliferation of clonal populations of T cells are critical for the initiation of an antigen-specific immune response. Thus, inhibition of T cell activation provides a potent means for suppressing specific immune response. A number of immunosuppressive agents exhibit the ability to suppress T cell activation.

Purification of Peripheral Blood Leukocytes and T Cells Peripheral blood leukocytes from normal donors are separated on Ficoll-Hypaque (Pharmacia, Piscataway, NJ). Leukocyte suspensions are washed in HBSS and are resuspended in RPMI 1664 medium (Gibco, Grand Island, NY) containing 10 % heat-inactivated fetal bovine serum and 100 U/ml penicillin/streptomycin. Leukocyte suspensions are resuspended in RPMI 1664 containing 10 % heat-inactivated pooled human serum. Highly enriched T cells are obtained by passing leukocytes through a nylon wool column to remove macrophages and B cells and then depleted of NK and monocytes with anti-Leu 11 b (Becton Dickinson, Mountain View, CA) plus complement (Pel-Freez, Brown Deer, WI). These highly enriched T cells are approximately 95 % CD 3+ cells, the remaining cells being B lymphocytes.

Peripheral blood leukocytes are incubated at 2 Â 10 5 /well with equal numbers of gammairradiated ( where CPM expt is mean counts per min of experimental cultures; CPM bckgrd is mean counts per min of background well, unstimulated cultures; and CPM ctrl is mean counts per min of uninhibited, stimulated cultures.

Peripheral blood leukocytes and isolated T cells are cultured with anti-CD3 (5 ng/ml) plus PMA (5 ng/ml), anti-CD28 (1:5,000 dilution) plus PMA (5 ng/ml), or 100 U/ml rhuIL-2 in RPMI 1644 containing 10 % fetal bovine serum. Peripheral blood leukocytes or T cells are cultured at 2 Â 10 5 cell per well in a total volume of 200 μl/well. 

Supernatants/well (100 ml) are harvested 24 h after initiation of cultures of peripheral blood leukocytes or T cells stimulated with anti-CD3 or anti-CD28 plus PMA. IL-2 in the coculture supernatant is quantitated using a commercially available IL-2 ELISA kit. All experiments are performed in duplicate.

The expression of IL-2R on T cells stimulated for 48 h with anti-CD3 or anti-CD28 plus PMA is determined using FITC-conjugated anti-CD25 mABs (Becton Dickinson, Mountain View, CA). T cells are washed in HBSS and then stained with phycoerythrin-conjugated anti-CD3 mAB and fluorescein-conjugated antiCD25 mAB. The percent of cells coexpressing CD3+ and CD25+ is determined from 2,000 cells using an EPICS C flow cytometer (Coulter, Hialeah, FL).

Dose-response curves of inhibition of one-way mixed lymphocyte reaction and of IL-2 in the supernatant after stimulation with antiCD3 or anti-CD28 are established. Zielinski et al. (1993 Zielinski et al. ( , 1994 studied the influence of leflunomide on expression of lymphocyte activation expression markers (IL-2 and transferrin receptors) as well as on cell cycle and on IL-2 receptor gene expression. Calcineurin was found to be a key signaling enzyme in T lymphocyte activation and the target of immunosuppressive drugs (Clipstone and Crabtree 1993) .

The viability and function of T lymphocytes has been explored using different cellular isolation techniques (Klein et al. 2006) . A number of different vehicles have been shown to inhibit T cell proliferation which include the natural product silymarin (Morishima et al. 2010) , heavy metals and polychlorinated biphenyls (Frouin et al. 2010) , alternatively activated macrophages (Huber et al. 2010) , type I interferon (Marshall et al. 2011) , mesenchymal stem cells (Zinocker and Vaage 2012) , and the programmed cell death-1 receptor (Patsoukis et al. 2015) .

The stimulation of macrophages by antigen, complement, phorbolesters, etc., leads to elaboration of O 2 À and other oxygen metabolites. Superoxide ion (O 2 À ) and other highly reactive oxygen metabolites (radicals) form the basis for an efficient microbicidal system in vivo. Yet, when these radicals are released in response to self-antigens, tissue damage is often the result. Inhibition of this process can be regarded as a measure for immunomodulating effects of compounds. The oxygen metabolites can produce light-emitting reactions (chemiluminescence), which is measurable if amplified with suitable agents, such as the cyclic hydrazide luminol.

Procedure NMRI mice weighing 30 g or Sprague-Dawley rats weighing 250-300 g of either sex are used. (5-amino-2,3-dihydro-1,4phthalazinedione, Sigma) final concentration 25 μg/ml Ex Vivo Experiment Groups of six animals are treated for 6 days orally or subcutaneously with test compound or the standard (prednisolone acetate or leflunomide). They are decapitated and exsanguinated. Macrophages are obtained by flushing the peritoneal cavity with 10 ml saline, containing 250 IU heparin. The cells are pooled, washed several times, and suspended again at a final concentration of 2 Â 10 6 /200 μl.

For measurement in the luminometer, the following mixture is prepared:

200 μl macrophages (2 Â 10 6 ) 100 μl luminol solution (100 μg/ml) 100 μl phorbolmyristenacetate solution (3.5 μM)

Each sample is mixed thoroughly without the phorbolmyristenacetate solution, put into the luminometer, and counted at 2 min intervals for 10 s. The addition of the phorbolester induces the reaction.

To 100 μl of macrophage suspension (2 Â 10 6 cells) is added 100 μl of the solution of the test compound and incubated for 15 min at 37 C.

Then, 100 μl of luminol solution (100 μg/ml) and 100 μl of the 3.5 μM phorbolester solution are added and the luminescence measured in the luminometer.

The time of maximal counts for the positive control is recorded. For all groups, the ratio of counts per 10 s is determined at that time, compared to the positive control counts per 10 s, and the percent change is calculated. For statistical evaluation, the experimental group is compared with the positive control group using Student's t-test. Bird and Giroud (1985) described a technique of polymorphonuclear leukocyte chemiluminescence as a means to detect compounds with anti-inflammatory activity. Inflammatory polymorphonuclear leukocytes were obtained by injecting rats intrapleurally with 1 ml of a 1 % solution of calcium pyrophosphate and collection of the pleural exudate 4 h later. Chemiluminescence responses were measured using a Packard Picolite chemiluminometer and opsonized zymosan as the stimulus. Seeds et al. (1985) found an independent stimulation of membrane potential changes and the oxidative metabolic burst in polymorphonuclear leukocytes.

A microtechnique for studying chemiluminescence response of phagocytes using whole blood was described by Selvaraj et al. (1982) . Traykov et al. (1997) investigated the effects of phenothiazine compounds on activated macrophage-induced luminal-dependent chemiluminescence, and Szliszka et al. (2013) studied the anti-inflammatory activity of artepillin C, a constituent of the resinous green propolis. Van Dyke et al. (2003) explored the use of lucigeninbased chemiluminescence assay to interrogate various inflammatory stages. inflammatory cells measured by a simple chemiluminescence method. Arzneim Forsch/ Drug Res 40:767-770 Merétey K, Boehm U, Falus A (1983) Chemiluminescence response of human blood mononuclear cells to PAH and histamine. Agents Actions 13:237-240 Seeds MC, Parce JW, Szeijda P, Bass DA (1985) Independent stimulation of membrane potential changes and the oxidative metabolic burst in polymorphonuclear leukocytes. Blood 65:233-240 Selvaraj R, Sbarra AJ, Thomas GB, Cetrulo CL, Mitchell GW (1982) A microtechnique for studying chemiluminescence response of phagocytes using whole blood and its application to the evaluation of phagocytes in pregnancy. J Reticuloendothel 

Purpose and Rationale Identification of antibody-producing cells is based on the ability of the secreted IgM antibody to fix complement and thereby lyse the indicator erythrocytes. Spleen cells or peripheral blood lymphocytes, previously incubated with antigen, are mixed with sheep red blood cells (SRBC) . After addition of complement and incubation, plaques (clear areas) caused by the lysis of SRBC appear in the otherwise cloudy layer. Antibody-forming cells can be detected by the appearance of plaques. The number of plaques obtained is proportional to the number of antibody-producing lymphocytes in the cell population.

Procedure NMRI mice weighing 16-18 g or Lewis rats weighing 180-200 g of either sex are used.

• Absorbed guinea pig complement • SRBC stored in Alsever's solution

Negative Control Spleen cells incubated with medium alone. The animals are decapitated and the spleens are removed from the peritoneal cavity. A single cell suspension of 15 Â 10 6 cells/ml is prepared. For the induction of PFC, a 0.5 ml splenocyte suspension is added to 0.5 ml of a suspension of SRBC, previously washed in medium and diluted to 8 Â 10 6 cells/ml. Thereafter, 1 ml of the solution of the test compound is added, and the limbrowells are incubated at 37 C in a CO 2 incubator for 5 days. Per group 3 limbrowells are set up. On day 5, the three wells of each group are pooled and washed in medium, and the number of cells is determined. For each cell pellet, 875 μl of washed SRBC and 125 μl absorbed guinea pig complement are added. The suspension is mixed thoroughly and filled in chambers constructed of microslides. The chambers are placed in the incubator at 37 C for 90-120 min. The plaqueforming colonies are counted immediately after incubation.

Purpose and Rationale Dihydroorotate dehydrogenase catalyzes the fourth committed step in the de novo biosynthesis of pyrimidines. As rapidly proliferating human T cells have an exceptional requirement for de novo pyrimidine biosynthesis, small-molecule dihydroorotate dehydrogenase inhibitors constitute an attractive therapeutic approach to autoimmune diseases, immunosuppression, and cancer. The main mode of action of the immunosuppressive compound leflunomide and its active metabolites is considered to be the inhibition of the enzyme dihydroorotate dehydrogenase (Bruneau et al. 1998; Graul and Castañer 1998; Knecht and Löffler 1998; R€ uckemann et al. 1998; Herrmann et al. 2000; .

A fragment of human dihydroorotate dehydrogenase is expressed by means of the baculovirus expression vector system and purified to a specific activity greater than 50 U/mg (Knecht et al. 1996 (Knecht et al. , 1997 . Enzyme assays are performed with purified recombinant dihydroorotate dehydrogenase at 30 C. The oxidation of the substrate dihydroorotate and the reduction of the co-substrate quinone is coupled to the reduction of the chromogen 2,6-dichlorophenolindophenol (DCIP). The reaction mixture contains 0.1 mM Q D or 0.1 M Q 10 , 1 mM L-dihydroorotate, 0.06 mM DCIP, 0.1 % Triton X-100 in 50 mM Tris-HCl buffer, 150 mM KCl, and pH 8.0. The reaction is started by addition of the enzyme. The loss of absorbance of the blue DCIP is monitored at 600 nm: = 18.800 l mol À1 cm À1 . The enzyme activity in control assays without Q D or Q 10 which is approximately 1 % of maximum enzyme activity is subtracted from the activity values measured. Stock solutions of the test compounds are prepared in dimethyl sulfoxide with further dilutions in the buffer taken for the assays.

To determine the inhibitory potency of the agents, the initial velocity of dihydroorotate dehydrogenase reaction is measured at saturating substrate concentrations, 1 mM dihydroorotate and 100 μM Q D , and varying concentrations of the drugs (1 nM through 100 μM). The equation is fitted to the initial velocities:

is the inhibitor concentration) in order to find the concentration causing 50 % inhibition of the enzyme activity (IC 50 ). Both virtual (Diao et al. 2012 ) and high-throughput screening (Baldwin et al. 2005) and have been used to identify micromolar and sub-micromolar, respectively, inhibitors of DHODH activity. Recently, DHODH has emerged as a therapeutic target in bovine babesiosis (2014).

(1998) De novo pyrimidine biosynthesis in Jurkat T cells is inhibited by leflunomide's primary metabolite A77-1726 at the level of dihydroorotate dehydrogenase. Int J Immunother 14: [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] Sphingosine 1-Phosphate

Sphingolipids have emerged as molecules whose metabolism is regulated to generation of bioactive products including ceramide, sphingosine, and sphingosine-1-phosphate. The balance between cellular levels of these bioactive products is recognized to be critical to cell regulation and may be a promising approach to tumor therapy and multiple sclerosis Rosen et al. 2013; Blaho and Hla 2014) , whereby ceramide and sphingosine cause apoptosis and growth arrest phenotypes and sphingosine-1phosphate mediates proliferative and angiogenic responses. Sphingosine kinase is a key enzyme in modulating the levels of these lipids (Hannun and Obeid 1995; Hofmann and Dixit 1998; Mathias et al. 1998; Prieschl et al. 1999; Pyne and Pyne 2000; Cummings et al. 2002; MacKinnon et al. 2002; Rosen and Liao 2003; Chen et al. 2004; Deguchi et al. 2004; Lee et al. 2004; Peng et al. 2004; Cyster 2005; Kee et al. 2005; Watterson et al. 2005; Gardell et al. 2006; Taha et al. 2006) . Ceramide formation and degradation are influenced by nitric oxide (NO) (Huwiler et al. 1999a, b; Franzen et al. 2002a, b) . 

At least five subtypes of the sphingosine 1-phosphate receptor with tissue specificity are known (Meyer zu Heringdorf et al. 1998; Kon et al. 1999; Im et al. 2000 Im et al. , 2001 Hale et al. 2004a; Sanna et al. 2004; Zhou and Murthy 2004; Xin et al. 2004; Lepley et al. 2005; Kimura et al. 2006; Kitano et al. 2006) . The immunomodulator FTY720 is an agonist to sphingosine 1-phosphate receptors (Brinkmann et al. , 2010 Brunkhorst et al. 2014; Chiba 2005; Chiba et al. 2011 Chiba et al. , 2014 Gräler and Goetzl 2004; Kunzendorf et al. 2004; Xin et al. 2004; Albert et al. 2005; Bandhuvula et al. 2005; Sawicka et al. 2003 Sawicka et al. , 2005 Habicht et al. 2005; Takasugi et al. 2013; Xin et al. 2006; Zhang et al. 2013; Zhou et al. 2006) . FTY720 is derived from ISP-1 (myriocin), a fungal metabolite that is an eternal youth nostrum in traditional Chinese herbal medicine (Fujita et al. 1994) . The compound {2-amino-2-[2-(4-octophenyl) ethyl]propane-1,3-diol} is a highly potent immune modulating agent.

Further derivates such as sphingosine 1-phosphate receptor agonists (Hale et al. 2004b, c; Clemens et al. 2005; Foss et al. 2005; Galicia-Rosas et al. 2012; Guerrero et al. 2013; Kiuchi et al. 2005; Komiya et al. 2012; Jin et al. 2014; Jo et al. 2005; Li et al. 2005; Colandrea et al. 2006; Sanada et al. 2011; Satsu et al. 2013; Sobel et al. 2013; Ren et al. 2012; Yamamoto et al. 2014 ) and antagonists Kennedy et al. 2011; Angst et al. 2012 ) have been described, and a patent review of sphingosine 1-phosphate receptors has been conducted . used the [γ-35 S] GTPS-binding assay to study the binding of the immune modulator FTY720 to sphingosine 1-phosphate receptors. studied the binding of sphingosine 1-phosphate agonists on distinct receptor subtypes.

Receptors and Cell Lines CHO cells stably expressing human S1P 1,2,3,4,5 were used (Mandala et al. 2002) . cDNA sequences encoding rodent S1P receptors were cloned from genomic DNA by polymerase chain reaction using the following primers for each respective receptor: 5 0 -GAACCCGGGTGTCCACTAGCATCCC GG and 5 0 CCCGAATTCTTAGGAAGAA-GAATTGACGTTTCC (mouse S1P 1 ), 5 0 -GAACCCGGGCGGCTTATACTCAGAGTACC and 5 0 -GGCGAATTCTCAGACCACTGTGTTA CCCTC (mouse S1P 2 ), 5 0 -GAACCCGGGCAA CCACGCATGCGCAGG and 5 0 -GTCGAA TTCTCACTTGCAGAGGACCCCG (mouse S1P 3 ), 5 0 -GAACCCGGGAACATCAGTA CCTGGTCCACGC and GCGGAATTCTA GGTGCTGCGGACGCTGG (mouse S1P 4 ), 5 0 -GAACCCGGGCTGCTGCGGCCGG and 5 0 -CGCGAATTCAGTCTGTAGCAGTAGGCACC (mouse S1P 5 ), 5 0 -GTAGGATCCGTGTCCTCCA CCAGCATC and 5 0 GGCCGAATTCTTAAGAA GAAGAATTGACGTTTC (rat S1P 1 ), 5 0 -GAA CCCGGGCATCCACGCATGCGCAG and 5 0 -GCCGAATTCTCACTTGCAGAGGACCCCA TTCTG (rat S1P 3 ).

The polymerase chain reaction products were inserted in-frame after a FLAG tag using vector pCMV-Tag2 (Stratagene, La Jolla, Calif., USA). Stable lines were established by transfecting plasmids into CHO cells using Lipofectamine reagent, selecting for neomycin resistance, and screening single cell cultures for increased [ 33 P] S1P-specific binding. Membranes were prepared from positive clones and confirmed in [ 33 P]S1P and [ 35 S]GTPγS binding assays.

Binding assays were conducted as described by Mandala et al. (2002) . [ 33 P]S1P was sonicated with fatty-acid-free bovine serum albumin, added to test compounds diluted in dimethyl sulfoxide (DMSO), and mixed with membranes in 200 μl in 96-well plates with assay concentrations of 0.1 nM[ 33 P]S1P (22,000 dpm), 0.5 % bovine serum albumin, 50 mM HEPES-Na (pH 7.5), 5 mM MgCl 2 , 1 mM CaCl 2 , and 0.3-0.7 μg of membrane protein. Binding was performed for 60 min at room temperature and terminated by collecting the membranes onto GF/B filter plates with a Packard Filtermate Universal harvester. Filter-bound radionuclide was measured on a Perkin Elmer 1450 MicroBeta. Specific binding was calculated by subtracting radioactivity that remained in the presence of 1,000-fold excess of unlabeled S1P.

To measure functional activation of the S1P receptors, [ 35 S]GTPγ S binding was measured. Membranes (1-4 μg of protein) were incubated in 96-well plates with test compounds diluted in DMSO in 100 μl of buffer containing 20 mM HEPES (pH 7.4), 100 mM NaCl, 10 mM MgCl 2 , and 2-10 μM GDP, depending on the expressed receptor. 

Purpose and Rationale Sphingosine 1-phosphate produced by two sphingosine kinase isoenzymes, denoted SphK1 and SphK2, is the ligand for a family of specific G-protein-coupled receptors that regulate cytoskeletal rearrangements and cell motility. Unlike the proliferative action of SphK1, the isoenzyme SphK2 has been shown to possess antiproliferative and proapoptotic action. Both kinases have been cloned and functionally characterized (Kohama et al. 1998; Liu et al. , 2003 Nava et al. 2000; Olivera et al. 2000; Igarashi et al. 2003; Paugh et al. 2003; Sanchez et al. 2003; Billich et al. 2005; Döll et al. 2005; Okada et al. 2005; De Palma et al. 2006; Zemann et al. 2006; Gao and Smith 2011; Neubauer and Pitson 2013; Tonellli et al. 2013; Zhang et al. 2013; Ceccom et al. 2014; Plano et al. 2014; Shen et al. 2014; Tamashiro et al. 2014; Tous et al. 2014) . A recent summary of drugs in clinical trials targeting the sphingosine 1-phosphate pathway illustrates the potential roles of this axis in cancer and autoimmune inflammatory disease (Kunkel et al. 2013) .

Sphingosine kinase activity assays were performed in a similar way by Paugh et al. (2003) and by .

In vitro kinase reactions were performed according to Olivera et al. (2000) . In brief, 30 μg of protein lysates was incubated with 50 μmol/l of sphingosine (dissolved as 1 mmol/l stock solution in 4 mg/ml of BSA in PBS) and 10 μCi (370 kBq) of [γ-32 P]ATP for 15 min at 37 C. For SK-2 activity assay, the same buffer including 1 M KCl was used to inhibit SK-1 activity . Reactions were terminated by addition of 20 μl of 1 N HCl followed by 800 μl of chloroform/methanol/HCl (100:200:1, v/v), 240 μl of chloroform, and 240 μl of 2 mol/l KCl. After vigorous vortexing and phase separation, 50 μl of the lower organic phase was loaded onto Olivera A, Barlow KD, Spiegel S (2000) Assaying sphingosinekinase activity. Purpose and Rationale Adaptive immunity depends on T cell exit from the thymus and T and B cells traveling between secondary lymphoid organs to survey for antigen. After activation in lymphoid organs, T cells must again return to circulation to reach sites of infection. The immunomodulatory drug FTY720 induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing via the S1P receptor 1 (Chiba et al. 1998; Yanagawa et al. 1998a, b; Henning et al. 2001; Matloubian et al. 2004; . Mandala et al. (2000) described alteration of lymphocyte trafficking by sphingosine 1-phosphate receptor agonists.

Induction of Lymphopenia and Reduction of Thoracic Duct (TD) Lymphocytes by S1P and Analogues in Rats Blood or thoracic duct lymph lymphocyte counts were determined by autoanalyzer (H2000, CARESIDE, Culver City, Calif., USA) and normalized to counts in vehicle controls after administration of FTY720 (2.5 mg/kg p.o.) or test compound. S1P was administered by continuous infusion beginning at 8 mg/kg/h for 20 min followed by 2 mg/kg/h for a further 220 min. The measured physiological S1P concentration in rat plasma by LC-MS was 0.5 μg/ml. This rose to a C max of 2.5 μg/ml at 30 min and was maintained at 1.5 μg/ml for the remainder of the experiment. Studies on the effect on lymphocyte numbers in thoracic duct-cannulated rats were performed after the administration of FTY720 or test compound. Lymph flow remained constant for the duration of the experiment, and numbers are shown as the average cell concentration maintained over the preceding 30 min.

Percentage depletion by FTY720 compared to vehicle control was measured. Similar nadir lymphopenia was produced by FTY720 or non-metabolizable phosphonates. Peripheral blood samples were diluted 1:1 with phosphatebuffered saline (PBS), layered on the same volume of Lymphocyte Separation Medium (ICN Biomedicals, Aurora, Ohio, USA), and centrifuged at 400 g for 30 min. Peripheral blood mononuclear cells (PBMC) were resuspended in PBS and counted using a hemocytometer. PBMC were then stained with FITC-labeled anti-CD8, PE-labeled anti-CD45RA, and Cy-chromelabeled anti-CD4 antibodies. Numbers of CD4-, CD8-, and CD45RA-positive cells were calculated by multiplying total PBMC count with the percentages of CD4 + , CD8 + , and CD45RA + generated from flow cytometry.

Single cell suspensions were prepared by passage of tissues through a 40-μm sieve. Peripheral blood lymphocytes were further isolated from spleens by ammonium chloride lysis of red blood cells. Cells were subsequently washed in UltraCULTURE medium (Biowhittaker, Walkersville, Md., USA), and all samples were adjusted to the same volume with PBS. An equal volume of 4 % paraformaldehyde was added while gently vortexing the samples. The total number of viable, unstained lymphocytes per sample was determined by flow cytometry (FACScan; Becton Dickinson) using CellQuest software (Becton Dickinson), based upon forward-and side-scatter characteristics. Beads (Sigma; P7458) were used as an internal standard.

Data were calculated as cell number per node by dividing the total number of lymphocytes quantitated by the number of nodes harvested per site (i.e., the number of Peyer's patches and mesenteric or peripheral lymph nodes collected). Kawa et al. (1997) reported inhibition of chemotactic motility and trans-endothelial migration of human neutrophils by sphingosine 1-phosphate. Fueller et al. (2003) described activation of human monocytic cells by lysophosphatidic acid and sphingosine-1-phosphate. Roviezzo et al. (2004) studied human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate. Kunisawa et al. (2007) showed that sphingosine 1-phosphate may regulate peritoneal B cell trafficking and Thangada et al. (2010) using adoptive transfer experiments in wild-type mice, and mice mutated for the sphingosine 1-phosphate receptor showed that cell surface residency of the receptor determines the kinetics of lymphocyte egress. showed that fingolimod (FTY720) may prevent inflammation-sensitized hypoxic ischemia brain injury in newborn rats. (Bielschowski et al. 1959; Howie and Helyer 1968; Barthold et al. 1974; Blanchard and Bach 1980) . The NZB mouse develops a spontaneous autoimmune disease with autoimmune hemolytic anemia, splenomegaly, glomerulonephritis, lymphoproliferative disorders, and peptic ulcerations.

New Zealand black/white F1 (B/W) mouse (Helyer and Howie 1963; Kessler 1968 ). These animals develop nephritis similar to that in human systemic lupus erythematosus and show mononuclear cell infiltration in salivary and lachrymal glands such as in human Sjögren's syndrome.

A substrain of the autoimmune-prone mouse, NZB/kl, was found to show spontaneous elevation of the auditory brainstem response threshold with age (Sone et al. 1995) .

Immunodeficient alymphoplasia mice were recommended as a spontaneous model for Sjögren's syndrome (Tsubata et al. 1996) . Mice homozygous for an autosomal-recessive mutation aly (alymphoplasia) lack both lymph nodes and Peyer's patches and show defects in both humoral and cellular immunity. Histopathological analyses revealed chronic inflammatory changes in exocrine organs such as the salivary gland, the lacrimal gland, and the pancreas.

The Palmerston North autoimmune mouse strain which exhibits both spontaneous systemic autoimmune disease and otic capsule bone formation has been proposed as a model for otic capsule osteogenesis and otosclerosis (Hertler and Trune 1990; Traynor et al. 1992) .

In aging BDF1 mice, Hayashi et al. (1988) described spontaneous development of autoimmune sialadenitis. Robison et al. (1994) examined the relationship between orchitis and aspermatogenesis in various strains of H 2 congenic mice and defined a genetic predisposition to spontaneous aspermatogenesis.

Motheaten mice. Mice homozygous for the autosomal-recessive motheaten (me) or the allelic viable motheaten (me v ) mutations develop severe and early-age onset of systemic autoimmune and inflammatory disease (Green and Shultz 1975; Shultz et al. 1984; Shultz 1988; Su et al. 1998) .

The genetic, hormonal, and behavioral influence on spontaneously developing arthritis in normal mice has been reviewed by Holmdahl et al. (1992) .

Nonobese diabetic mouse (NOD mouse) (Makino et al. 1980; Miyazaki et al. 1985; Leiter et al. 1987) . The inbred NOD mouse is considered a good model for type I diabetes mellitus. Mononuclear cells infiltrate the pancreatic islets of Langerhans from 6 to 8 weeks of age, followed by a progressive and selective destruction of insulin-producing β-cells and the onset of IDDM from the 12th week of age onwards. Itoh et al. (1997) studied the requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. Quartey-Papafio et al. (1995) showed that aspartate at position 57 of nonobese diabetic I-A (g7) β-chain diminishes the spontaneous incidence of insulin-dependent diabetes mellitus in the NOD mouse.

The NOD mouse was also recommended to study the pathogenesis of autoimmune thyroiditis Giarratana et al. 2007) . Bio-breeding rat (BB rat) (Like et al. 1982; Field 1983; Yale and Marliss 1984) . On the basis of clinical and histopathological parameters, the BB rat is considered a useful model for human IDDM. The disease in the BB rat is characterized by infiltration of lymphocytes and macrophages into the islets of Langerhans.

Allen and Thupari (1995) described spontaneous autoimmune lymphocytic thyroiditis in BB/Wor rats.

Obese strain chicken (OS chicken) (van Tienhoven and Cole 1962; Cole 1966; Cole et al. 1968 Cole et al. , 1970 Wick et al. 1974) . The OS chicken is perhaps the best studied model for an organ-specific, spontaneously occurring autoimmune disease, viz., spontaneous autoimmune thyroiditis, which closely resembles human Hashimoto thyroiditis. The spontaneous autoimmune thyroiditis in obese chicken was further studied by Neu et al. (1986) , Kroemer et al. (1989) , Cihak et al. (1995) , Hala et al. (1996), and Dietrich et al. (1997) .

Chickens of the University of California line 200 (UCD-200 chickens) develop an inherited inflammatory fibrotic disease that closely resembles human progressive systemic sclerosis (scleroderma) (Gershwin et al. 1981 ; Van de Water et al. 1984; Brezinscheck et al. 1993) .

Schumm-Draeger and Fortmeyer (1996) described autoimmune thyroiditis in the cat as a spontaneous disease model.

Spontaneous autoimmune thyroiditis was found in Mastomys (Praeomys coucha) by Solleveld et al. (1985) and recommended as an animal model of human disease. Barthold DR, Kysela S, Steinberg AD (1974) Decline in suppressor T cell function with age in female NZB mice. J Immunol 112:9 Bielschowski M, Helyer BJ, Howie JB (1959) Spontaneous anemia in mice of the NZB/BL strain. Proc Univ Otago Med Sch 37:9-11 Blanchard D, Bach MA (1980) 

Purpose and Rationale Rats are immunized with ovalbumin and Bordetella pertussis suspension as adjuvant.

After 11 days, the animals are challenged by intravenous injection of ovalbumin. The shock symptoms can by inhibited by corticosteroids and intravenous disodium cromoglycate.

Female Sprague-Dawley rats weighing 120 g are immunized by i.m. injection of 10 mg/kg highly purified ovalbumin. Simultaneously 1 ml of Bordetella pertussis suspension (2 Â 10 10 organisms) is injected intraperitoneally. IgE antibodies are induced and attached to the surface of mast cells and basophilic granulocytes. Eleven days later, the animals are challenged by intravenous injection of 25 mg/kg highly purified ovalbumin. This results in the formation of antigen-antibody complexes on the surface of mast cells and basophilic granulocytes in blood and in all organs with immediate release of various mediators of anaphylaxis, such as histamine, serotonin, SRS-A, and prostaglandins; in shock symptoms; and 80 % lethality. Corticosteroids, e.g., dexamethasone 1-10 mg/kg s.c., are given 18 h prior to challenge or 30 mg/kg disodium cromoglycate i.v. before injection of ovalbumin. Ten to 20 animals are used for each group.

The shock symptoms are scored and mortality counted. Results after treatment are compared with untreated controls. Pretreatment with corticosteroids or disodium cromoglycate can inhibit death and ameliorate shock symptoms. Statistical calculation is performed using the χ 2 -test.

Desensitization by repeated "microshocks" of constant strength in guinea pigs has been reported by Herxheimer (1952) . Acute systemic anaphylaxis experiments have also been performed in guinea pigs and in mice. In guinea pigs, anaphylactic bronchospasm can be measured with the Konzett and Rössler method (Davies and Evans 1973) .

Moreover, anaphylactic bronchospasm can be measured in isolated guinea pig lungs according to the method of Bhattacharya and Delaunois (1955) .

Anaphylaxis can be measured in the chopped guinea pig lung by assay of the supernatant in the isolated guinea pig ileum in the presence of 2 Â 10 À7 M atropine (Austen and Brocklehurst 1961) . Ufkes and Ottenhof (1984) sensitized Brown Norway rats with a suspension of trinitrophenylhaptenized ovalbumin together with AlPO 4 as adjuvant. Bronchial and cardiovascular functions were studied after treatment with antiallergic agents and antigen challenge. Elwood et al. (1992) studied the effect of dexamethasone and cyclosporine A on allergeninduced airway hyperresponsiveness and inflammatory cell responses in sensitized Brown Norway rats. Anti-anaphylactic Activity (Schultz-Dale Reaction)

Purpose and Rationale Guinea pigs are sensitized against egg albumin. Challenge after 3 weeks causes in isolated organs' release of mediators, e.g., histamine, which induce contraction in isolated ileum.

Guinea pigs of either sex weighing 300-350 g are sensitized with alum-precipitated egg albumin. Alum egg albumin is prepared by dissolving egg albumin (1 mg/ml) in 6 % aluminum hydroxide gel, suspended in saline. The mixture is stirred and kept at room temperature. Each animal receives at the same time injections of 0.125 ml of this mixture in each foot pad and 0.5 ml subcutaneously. After 4 weeks, the animals are killed and the ileum is dissected out. Cleaned pieces, about 2-3 cm long, are mounted in an organ bath containing Tyrode solution at 37 C. The strips are allowed to equilibrate for 15 min. The contractility of the ileum strips is tested by adding 10 À4 g/ml BaCl 2 solution. To one organ bath the standard (2 Â 10 À6 g/ml final concentration of tribenoside = 1-O-ethyl-3,5,6-tri-O-benzyl-Dglucofuranoside = Glyvenol CIBA) and to other vials the test compounds (final concentration up to 10 À5 g/ml) are added. One organ bath serves as control. After 3 min, ovalbumin in a final concentration of 2 Â 10 À6 g/ml is added. The contractions are recorded with strain gauges by a polygraph.

The results are expressed as presence or absence of blocking activity (percentage inhibition). If anti-anaphylactic activity is observed, ED 50 values using different doses are calculated.

Positive results can also be achieved with spasmolytics, local anesthetics, antihistaminics, and sympathicomimetics.

The method has been modified by testing histamine release in the lung after challenging with egg albumin. Either lung strips from sensitized guinea pigs are suspended in an organ bath and their contractions are measured after addition of egg albumin or the entire lung tissue is dissected out and washed free from blood by perfusing with warm oxygenated Tyrode solution via the pulmonary artery. The lung tissue is chopped and washed with Tyrode solution in order to remove the remaining blood. The chopped lung tissue is divided into 24 samples, each of approximately 100 mg wet weight. These are incubated at 37 C in Tyrode solution for 15 min with continuous agitation by rocking, after which 1 mg/ml of egg albumin is added to the reaction mixture. After shaking for 10 min at 37 C, the supernatant is collected and assayed for histamine with guinea pig ileum. Atropine sulfate 2 mg/ml is added in Tyrode solution. The residual histamine is obtained by boiling the tissue in 5 ml Tyrode solution for 10 min. The tubes are then placed on ice for 1 h to allow complete diffusion.

Released histamine is expressed as a percentage of total histamine content. Koppel et al. (1981) developed a method to induce contraction of immunologically sensitized mouse trachea by antigen (Schultz-Dale reaction).

The trachea of sensitized guinea pigs was used by Omote et al. (1994) . Choi et al. (2008) 

Purpose and Rationale Passive cutaneous anaphylaxis is an immune reaction of the immediate type. By passive immunization of rats in the skin with rat antiovalbumin serum and a challenge 2 days later with ovalbumin at the same skin area, antigen-antibody complexes are formed in the mast cells inducing release of mediators. This results in vasodilatation, increase in permeability of the vessel walls, and leakage of plasma. To make the allergic reaction visible, Evan's blue dye is administered along with the antigen. Evan's blue dye is attached to the albumin fraction of plasma, producing a blue spot. This blue spot indicates that an anaphylactic reaction has taken place in the skin.

For preparation of antiserum, male rats weighing 200-250 g are adrenalectomized and are allowed to recover for 3 days. Thereafter, animals are sensitized with egg albumin (1 mg/animal) using aluminum hydroxide gel (200 mg) as adjuvant. Alum egg albumin is prepared by dissolving 1 mg/ml of egg albumin in 20 % aluminum hydroxide gel, suspended in saline. Each animal simultaneously receives 0.125 ml of the above solution in each foot pad and 0.5 ml subcutaneously. After 8 days, the animals are bled and antiserum is collected.

For the test, the antiserum is diluted in such a manner as to give a wheal of 15-20 mm diameter in a preliminary titration. Aliquots of 100 μl of appropriate dilution of antiserum are injected intradermally into the shaved dorsal skin of normal male rats weighing about 100 g. After 24 h of latent period, each animal is challenged with the intravenous administration of 0.1 ml of 2.5 % Evans blue dye containing 25 mg/ml of egg albumin. In the case of intravenous administration, the test compound is administered simultaneously with the antigen and the dye. In case of oral testing, the compound is given orally 1 h prior to challenge. The animals are sacrificed 30 min after the challenge. The amount of Evans blue dye leaked at the site of passive cutaneous anaphylactic reaction is extracted and determined colorimetrically at 620 μm wavelength.

The amount of Evans blue extracted from passive cutaneous anaphylactic reaction is taken as 100 %. Percent inhibition of passive cutaneous anaphylactic reaction in the rats treated with the test compound is calculated. The standard disodium cromoglycate at a dose of 3 mg/kg i.v. or 30 mg/kg orally results in 80-100 % inhibition. Using different doses, ED 50 values can be calculated.

Goose and Blair (1969) used Bordetella pertussis and extracts of the worm Nippostrongylus brasiliensis as antigens in passive cutaneous anaphylaxis experiments in the rat. Patterson et al. (1971) tested passive cutaneous reactivity to antihuman IgE in rhesus monkeys.

Without immunization, plasma extravasation after bradykinin injection can be tested in anesthetized Sprague-Dawley rats (Lembeck et al. 1991) . Evans blue dye is injected to stain plasma proteins. After injection of bradykinin antagonists followed by bradykinin injection, the rats are perfused with physiological saline. The trachea, the urinary bladder, and the duodenum are resected, weighed, and incubated for 48 h in formamide at 50 C (Saria et al. 1983 ). The amount of Evans blue extracted is measured photometrically at 620 nm.

Vascular reactions to histamine, histamine liberator, and leukotaxine in the skin of guinea pigs using pontamine sky blue 6Â as indicator were studied by Miles and Miles (1952) . Babakin et al. (2008) investigated the effects of fullerene-60 in both systemic and both rat and murine passive cutaneous models of anaphylaxis, and Zhu et al. (2009) showed that the proteinaseactivated receptor 2 is involved in passive cutaneous murine model of anaphylaxis and that it can be inhibited by tacrolimus. Hitomi et al. (2010) discovered that mice deficient in the immunoglobulin-like receptor Allergin-1 developed enhanced passive systemic and cutaneous anaphylaxis, and Han et al. (2013) showed that the phytoalexin resveratrol inhibited both IgE-mediated basophilic mast cell degranulation and passive cutaneous anaphylaxis in a murine model.

Babakin AA, Andrievsky G, DuBuske LM (2008) Inhibition of systemic and passive cutaneous anaphylaxis by water-soluble Fullerene 60. J Allergy Clin Immunol 123:S118 Goose J, Blair AMJN (1969) Passive cutaneous anaphylaxis in the rat, induced with two homologous reagin-like antibodies and its specific inhibition with disodium cromoglycate. Immunology 16:749-760 Griesbacher T, Lembeck F (1987) Actions of bradykinin antagonists on bradykinin-induced plasma extravasation, venoconstriction, prostaglandin E 2 release, nociceptor stimulation and contraction of the iris sphincter muscle of the rabbit. Br J Pharmacol 92:333-340 

Ovalbumin Suspension 1,700 mg ovalbumin is suspended in 100 ml paraffin oil. 4.38 ml pertussis vaccine is suspended in 70 ml 0.9 % NaCl solution. Both suspensions are mixed to form an emulsion. Wistar or Sprague-Dawley rats of either sex weighing 220-280 g can be used. Seven days prior to the start of the experiment, rats are sensitized by i.m. administration of 0.5 ml of the ovalbumin suspension. They are housed in groups of eight with standard food and water ad libitum.

Twenty-four hours and 1 h prior to induction of the Arthus reaction, test compounds are administered to groups of eight animals. The rats are challenged by injection of 0.1 ml of 0.04 % solution of highly purified ovalbumin in the left hind paw. Swelling of the paw occurs which reaches a maximum after a few hours. The footpad thickness can be measured by calipers. One group of sensitized animals treated with solvent alone serves as positive control; one group of non-sensitized animals treated with solvent alone serves as negative control. Standard doses are 30 mg/kg cortisone or 10 mg/kg prednisolone p.o.

The change in footpad thickness is expressed as the percent change from the vehicle control group. Comparison of experimental group to positive control is evaluated statistically using Student's t-test.

Instead of ovalbumin, sheep red blood cell suspensions can be used for immunization and for challenge in mice (Omote et al. 1994) . sensitized mice by s.c. injection of bovine serum albumin in complete Freund's adjuvant and boosted on day 21 by an intradermal injection of BSA. On day 28, the Arthus reaction was elicited by intradermal injection of BSA. Four hours later, an erythematous skin reaction over an area of more than 8 mm 2 was regarded as positive. immunized guinea pigs by injection of a mixture of egg albumin and Freund's complete adjuvant subcutaneously into the food pad or i.m. into the hind leg. The injection was repeated four times at 7-day interval. Ten days after the last immunization, 0.2 ml of 2.5 % egg albumin was injected sc. into the dorsal skin of the animals. The intensity of the Arthus reaction was evaluated by measuring the inflamed area according to scores. 

Purpose and Rationale Delayed-type hypersensitivity is a reaction of cellmediated immunity and becomes visible only after 16-24 h. The same methods as for testing immediate-type hypersensitivity can be used.

Rats are sensitized in the same way by i.m. administration of 0.5 ml ovalbumin suspension 7 days prior to the start of the experiment as described for testing immediate-type hypersensitivity. They are challenged by injection of 0.1 ml of 0.04 % solution of highly purified ovalbumin in the left hind paw. Footpad thickness is measured immediately and 24 h after ovalbumin administration. Mizukoshi et al. (1994) injected female CDF1 mice intradermally with a suspension of 2 Â 10 8 sheep red blood cells/50 μl into the left foot pad. A second booster of the same dose was given to the right foot pad on day 4. The thickness of the foot pads was measured on the following day, and the difference in the thickness between the right and the left food pads was taken as the degree of swelling. immunized mice by applying 0.15 ml of 7 % picryl chloride/ethanol solution to the skin of the shaved abdomen. The second immunization was performed 6 days later. One week after the second immunization, 1 drop of 1 % picryl chloride olive oil solution was applied to the ear, and the thickness of the ear was measured by a thickness gauge 24 h later. Heriazon et al. (2009) investigated the induction of DTH and interferon gamma to Candida albicans and anti-hen egg white lysozyme antibody as phenotypic markers of enhance bovine immune response, and their studies suggest that this combination of test antigens could be used as phenotypic markers of immune responsiveness in cattle. Escandell et al. (2010) investigated the inhibition of DTH by the plant product cucurbitacin R which was shown to reduce human T lymphocyte proliferation. Yang et al. (2011) used the DTH model to a three-protein cocktail with that of a purified protein derivative, and Atkinson et al. (2012) extended the model to study the similarities with collagen-induced arthritis and human rheumatoid arthritis. 

In the reversed passive Arthus reaction, the antigen is injected intravenously followed by a local injectioneither intradermally or into the pleural spaceof the respective antibody. Generation of an immune-mediated reverse passive Arthus reaction in the rat pleural cavity results in a classic acute inflammatory response. The methods are used to evaluate new anti-inflammatory agents.

Male Lewis rats weighing 200-250 g are fasted overnight prior to use with free access to water. The animals receive 5 mg bovine serum albumin in 0.2 ml sterile saline intravenously, followed 30 min later by injection of 1 mg rabbit anti-BSA in 0.2 ml sterile saline into the right pleural cavity under light halothane anesthesia. Drugs or vehicle controls are administered by gastric gavage in 1 ml/100 g body weight at different times prior to the anti-BSA. The animals are sacrificed at various intervals after anti-BSA injections by CO 2 inhalation (after 5 min for thromboxane B 2 determination, after 10 min for leukotriene B 4 determination, and after 4 h at the peak time of neutrophil infiltration). The fluid exudate is removed from the pleural cavity by gentle vacuum aspiration and the volume is recorded. Eicosanoids in the pleural exudate are quantitated by commercial RIA kits.

The values after treatment with various doses of test compounds are compared with those of vehicle controls.

The antibody can be injected intradermally into the shaved skin of rats after intravenous injection of the antigen (e. g., human albumin) together with Evans blue dye solution. Extravasated dye is determined in skin punches (Camussi et al. 1990; Burch et al. 1992; Okamoto et al. 1992) . Bailey and Sturm (1983) induced the reverse passive Arthus reaction in rats using bovine serum albumin as antigen into the tail vein and rabbit anti-bovine serum albumin into the skin site. One hour after oral dosing with vehicle or drug, animals were lightly anesthetized and their hair was shaved from the middorsal region with electric clippers. Each animal was injected intradermally with 40 μl on the left side of the middorsal line and with 40 μl of rabbit anti-bovine serum albumin (5.0 mg/ml antibody protein), diluted 1:4 with phosphate-buffered saline on the right side of the dorsal midline. Immediately following the intradermal challenge, each rat received 0.5 ml phosphate-buffered saline containing 1.0 mg bovine serum albumin injected in the tail vein. Four hours after intradermal challenge, the animals were sacrificed. The full-thickness skin was removed from the back, and disks 8 mm in diameter were punched out with a metal punch. Wet weight of the samples from the phosphatebuffered saline-and antibody-injected site was determined, and the edema induced by the reverse passive Arthus reaction calculated as the difference between both weights. 

Purpose and Rationale Adjuvant arthritis in rats has been described by Pearson and Wood (1959) exhibiting many similarities to human rheumatoid arthritis. Injections of complete Freund's adjuvant into the rat paw induce inflammation as primary lesion with a maximum after 3-5 days. Secondary lesions occur after a delay of approximately 11-12 days which are characterized by inflammation of non-injected sites (hindleg, forepaws, ears, nose, and tail) and a decrease of weight and immune responses. The procedure has been modified by several authors in order to differentiate between anti-inflammatory and immunosuppressive activity (e.g., Perper et al. 1971) . Anti-inflammatory compounds do not inhibit secondary lesions, which are prevented or diminished by immunosuppressive agents. Two protocols, termed "preventative" (or "prophylactic") and "therapeutic" (or "established") adjuvant arthritis, have gained wide usage for assessing a drug's potential antiarthritic activity (Schorlemmer et al. 1999) .

The choice of the animal strain has been found to be very important for the performance of this test.

Wistar-Lewis rats have been proven to be very suitable in contrast to other substrains. Male rats with an initial body weight of 130-200 g are used.

On day 1, they are injected into the suplantar region of the left hind paw with 0.1 ml of complete Freund's adjuvant. This consists of 6 mg mycobacterium butyricum (Difco) being suspended in heavy paraffin oil (Merck) by thoroughly grinding with mortar and pestle to give a concentration of 6 mg/ml. Dosing with the test compounds or the standard is started on the same day and continued for 12 days. Paw volumes of both sides and body weight are recorded on the day of injection, whereby paw volume is measured plethysmographically with equipment as described in the paw edema tests. On day 5, the volume of the injected paw is measured again, indicating the primary lesion and the influence of therapeutic agents on this phase. The severity of the induced adjuvant disease is followed by measurement of the non-injected paw (secondary lesions) with a plethysmometer. Purposely, from day 13-21, the animals are not dosed with the test compound or the standard. On day 21, the body weight is determined again, and the severity of the secondary lesions is evaluated visually and graded according the following scheme: In contrast, immunosuppressants like cyclophosphamide at a dose of 7 mg/kg inhibited the secondary lesions even when started at day 9 or later.

Critical Assessment of the Method Evidence was given that adjuvant arthritis in the rat is associated with chronic pain (Colpaert 1987) . The measure of pain in this model still presents some technical problems since the evaluation is based on the somewhat biased observation of the behavioral responses.

A review was given by Gardner (1960) on the experimental production of arthritis. Moran et al. (1999) compared adjuvant arthritis and selected animal models of arthritis to rheumatoid arthritis with special emphasis on the mechanism of joint destruction. Kazuna and Kawai (1975) and Rooks et al. (1982) used rats with established lesions to test analgesics in the arthritic flexion pain test. The method is claimed to be specific by detecting only central analgesics and nonsteroidal antiinflammatory drugs but not other classes such as CNS-depressant or antihistaminic drugs. Brackertz et al. (1977) established antigeninduced arthritis in the mouse by immunization with methylated bovine serum albumin in complete Freund's adjuvant with B pertussis vaccine.

A streptococcal cell wall-induced arthritis in rats has been described by Wilder et al. (1982 Wilder et al. ( , 1987 and . Lewis et al. (1997) studied degradation of articular cartilage in a rat monoarthritis model induced by an intra-articular injection of Propionibacterium acnes. Crossley et al. (1989) reported on a monoarticular antigen-induced arthritis in rabbits and mice.

α-2-Glycoprotein levels have been recommended as parameter for severity and inhibition of experimental immunoarthritis in the rat by Sandow et al. (1971) . Pircio et al. (1975) recommended a method for the evaluation of analgesic activity using adjuvant-induced arthritis in rats. The degree of vocalization was recorded from five rats placed together in a counting chamber. Cruwys et al. (1994) sensitized rats on day 0 and 7 with multiple intradermal injections of methylated bovine serum albumin emulsified in Freund's complete adjuvant. On day 21, the animals were challenged by the intra-articular injection of 100 μl 0.5 % solution of methylated bovine serum albumin into the right knee. The progress of the monoarticular arthritis was monitored by daily measurement of joint diameter. Butler et al. (1991) described a limited arthritic pain model for chronic pain and inflammation studies using injections of 0.05 ml of complete Freund adjuvant into the left tibiotarsal joint of Sprague-Dawley rats. Issekutz et al. (1994) studied the role of tumor necrosis factor-alpha and IL-1 in polymorphonuclear leukocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Esser et al. (1995) measured radiographic changes in adjuvant-induced arthritis in rats by quantitative image analysis. Digitized radiographs of the calcaneus were examined for changes in the mean and in the distribution of gray values. Periostal new bone formation was measured as an increase in image area of the calcaneus.

Mercuric chloride (HgCl 2 ) induces a syndrome of autoimmunity in Brown Norway rats characterized by a variety of IgG antibodies; very high concentrations of serum IgE, proteinuria, leukocytoclastic vasculitis which predominantly affects the cecum; and an inflammatory polyarthropathy (Kiely et al. 1995 (Kiely et al. , 1996 . Kawahito et al. (2000) reported that 15-deoxy-Δ 12,14 -PGJ 2 which activates PPAR-α induces synoviocyte apoptosis and suppresses adjuvantinduced arthritis in rats. Cuzzocrea et al. (2002) found that prostaglandin 15-deoxy-Δ 12,14 -prostaglandin J 2 attenuates the development of acute and chronic inflammation. Bolon et al. (2004) described a method for rapid quantification of intralesional osteoclasts in the hind paws of Lewis rats with adjuvant-induced arthritis. A 4-μm-thick section of the decalcified hind paw was stained to demonstrate osteoclasts using an indirect immunoperoxidase method and a rabbit antihuman monoclonal antibody directed against the osteoclast marker cathepsin K, which is an osteoclast protease primarily responsible for the resorption of bone. The sections were evaluated using tiered, semiquantitative criteria to grade bone erosions and intralesional osteoclasts. Kong et al. (1999) , Campagnuolo et al. (2002) , and Bolon et al. (2002a, b) used Lewis rats with adjuvant arthritis to describe the effects of osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. Francischi et al. (2000) described antiinflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in the rat model of adjuvant-induced arthritis. Boyle et al. (2001) reported anti-inflammatory effects of a non-nucleoside adenosine kinase inhibitor in rat adjuvant arthritis. Fujisawa et al. (2002) demonstrated the effects of highly water-soluble matrix metalloproteinase inhibitors in a rat adjuvant-induced arthritis model. Wei et al. (2004) described the effects and mechanisms of a dual inhibitor of interleukin-1 and tumor necrosis factor on adjuvant arthritis in rats. Boe et al. (1999) reported that interleukin 6 knockout mice are resistant to antigen-induced experimental arthritis. Gauldie et al. (2004) described a robust model of adjuvant-induced chronic unilateral arthritis in two mouse strains. DBA/1 and C57BL/6 male mice were injected intra-articularly into a stifle joint with FCA (5 μg in 5 μl) once per week for 4 weeks. Measurements of joint diameter and joint histopathology were used to monitor the course of arthritis. Inflammatory hyperalgesia was assessed as the pressure causing a limb withdrawal. Standard drugs, such as indomethacin or prednisolone, caused a decrease in joint inflammation and associated hyperalgesia. Kim and Moudgil (2009) reviewed the genetic and other determinants of both susceptibility and resistance to adjuvant-induced arthritis in the rat, and Snekhalatha et al. (2013) conduced a detailed characterization of adjuvant-induced arthritis in the rat model comparing thermography, radiological imaging, and histopathology, a work extended by Vollmer et al. (2014) who used near-infrared fluorescence imaging to monitor the progress of experimental-induced arthritis in several rat models.

The adjuvant-induced arthritis model has been used to profile the activity of a number of candidate drugs which include DHOH, p38 and JAK inhibitors (Balague et al. 2012) , bee venom (Darwish et al. 2013) , peptides from heat shock protein 65 , and the saponin astragaloside IV (Wang 2014) . Consden et al. (1971) , , , and Jasin and Cooke (1977) produced a chronic experimental monoarthritis by intra-articular injection of antigens into previously immunized rabbits. Henderson et al. (1990) induced monoarticular arthritis in ovalbumin-sensitized rabbits by intraarticular injection of ovalbumin (antigen-induced arthritis) or in naive rabbits by injecting hyaluronic acid mixed with the polycation poly-D-lysine (polycation-induced arthritis). Arner et al. (1995) compared the alterations in proteoglycan metabolism in antigen-induced arthritis and polycation-induced arthritis in rabbits and determined the involvement of interleukin-1 in the cartilage degradation that occurs in these models of rheumatoid arthritis. Lewthwaite et al. (1995) studied the antifibrotic action of interleukin-1 receptor antagonist in antigen-induced monoarticular arthritis in New Zealand white rabbits.

Arthritis occurs in pigs due to infection with Erysipelothrix rhusiopathiae (Ajmal 1969) . Experimental erysipelothrix infection in pigs can be used as a model for rheumatism research (Schulz et al. 1975a (Schulz et al. , b, 1977 . Infections are established by oral or parenteral administration of standardized serotype B erysipelas strains.

Erysipelothrix arthritis could also be produced in rats and rabbits (White et al. 1975; Glynn 1977) .

Arthritis due to infection with Mycoplasma synoviae occurs naturally among domestic poultry (Olson et al. 1954 (Olson et al. , 1964 . Arthritis in chickens after mycoplasma infection has been used as experimental model (Kerr and Olson 1970; Cullen 1977) .

Experimental models of arthritis due to streptococcal infections have been proposed for various species: mice (Cayeux et al. 1966; Hook et al. 1960; Ohanian et al. 1969) , rats (Jasmin 1967; Koga et al. 1973) , rabbits (Cecil et al. 1939; Cook and Fincham 1966; Ginsburg et al. 1968 Ginsburg et al. , 1977 Norlin 1960; Shimizu et al. 1958; Stein et al. 1973) , and pigs (Roberts et al. 1968 (Roberts et al. , 1969 .

The injection of avridine [N,N-dioctadecyl-N 0 , N 0 -bis (2-hydroxyethyl) propanediamine/CP-20961], emulsified in Freund's adjuvant, at the base of the tail is arthritogenic in susceptible rat strains (Meacock et al. 1994; Brun et al. 1995; Vingsbo et al. 1995; Lorentzen and Klareskog 1997; Joe and Wilder 1999; Van Bilsen et al. 2004 ). 

Purpose and Rationale As reported by Trentham et al. (1977) , intradermal injection of homologous or heterologous type II collagen in incomplete Freund's adjuvant results in an inflammatory polyarthritis in rats. The demonstration of antibodies to collagen in patients with rheumatic polyarthritis suggests that autoimmunity may contribute to the pathophysiology of synovitis and joint destruction. Because of the similarities of the symptoms in rats to human disease, the test is considered to be useful to detect anti-inflammatory and immunosuppressive properties of test compounds.

Bovine type II collagen is prepared from nasal septum cartilage, which is cut into small fragments, frozen in liquid nitrogen, and pulverized in a freezer mill. Proteoglycans are extracted overnight by stirring 25 g of pulverized cartilage in 1 l of 0.2 N NaOH. Following centrifugation at 20,000 g for 30 min, the residue is washed with 250 ml of absolute ethanol, the supernatant aspirated, and the residue vacuum dried. Hundred mg pepsin is added to 150 ml of 0.5 M acetic acid, after which 1.0 g of cartilage is added to reach a cartilage to pepsin ratio of 10:1 (w/w). The mixture is stirred 18 h at room temperature and centrifuged at 20,000 g for 1 h. Acid soluble collagen present in the supernatant is precipitated by adding NaCl to reach a final concentration of 0.9 M, followed by centrifugation at 20,000 g for 1 h. The precipitate from 1.0 g cartilage is dissolved in 100 ml 1.0 N NaCl/0.005 M Tris-HCl, pH 7.5, and stirred for 3 days. Then, the solution is dialyzed against 0.02 M Na 2 HPO 4 , pH 9.4, and the precipitate collected by centrifugation at 30,000 g for 1 h. The pellet is dissolved in 0.5 M acetic acid, dialyzed against 6 l of 0.01 M acetic acid, and lyophilized. All procedures, unless otherwise stated, are performed at 4 C. Test procedure. Collagen is dissolved in a concentration of 2.0 mg/ml in 0.1 M acetic acid overnight at 4 C. This solution is added dropwise to an equal volume of chilled incomplete Freund's adjuvant. Six to 12 male Wistar rats with an initial weight of about 120 g are used for each group. On day 1, each rat receives a total of 0.5 mg collagen in 0.5 ml, equally divided, in five sites. All injections are intradermal, one at the base of each appendage and one in the nape of the neck. Seven days postimmunization, the animals receive identical booster injections. Control animals receive only the incomplete Freund's adjuvant diluted with 0.1 M acetic acid.

The volume of both hind paws is measured plethysmographically on day 20. To minimize the possibility of including animals with minimal transient disease, only animals with a paw volume of 1.8 ml or greater are used for further testing. From days 20-40, the animals receive the test compounds p.o. once a day. On day 41, the paw volumes are recorded again.

The paw volumes of treated animals are recorded plethysmographically. The increase versus day 20 is calculated. The increase is compared with that of controls or animals treated with a standard drug. Otherwise, arthritic scores can be determined. Nonsteroidal anti-inflammatory drugs such as indomethacin in a dose of 2 mg/kg p.o. or phenylbutazone in a dose of 150 mg/kg p.o., but not acetylsalicylic acid in a dose of 50 mg/kg p.o., have been found to be active. Likewise, corticosteroids and immunosuppressives, but not D-penicillamine, were active.

Nonsteroidal and steroidal anti-inflammatory compounds are detected by this method which, however, does not allow a separation between these two groups.

From studies with a neutrophil elastase inhibitor, Janusz and Durham (1997) concluded that the destruction of the joints in rat collagen-induced arthritis is at least partially due to neutrophil elastase. Romas et al. (2002) reported that osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis in Dark Agouti rats. Hom et al. (1988) , Takagishi et al. (1986 Takagishi et al. ( , 1992 , Cannon et al. (1990) , , and described the effects of immunomodulating agents in collagen-induced arthritis in mice. Wooley et al. (1993) investigated the antiarthritic effect of recombinant human interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Joosten et al. (1994) found an accelerated onset of collagen-induced arthritis in DBA 1 lac/J mice by remote inflammation. Miesel and Haas (1993) , Miesel et al. 1994a , b) studied the effects of an active center analogue of Cu 2 Zn 2 -superoxide dismutase in collagen type II-induced arthritis. Furthermore, the authors described a model potassium peroxochromateinduced inflammation in rats and mice. One to 3 μmol/kg K 3 CrO 8 was administered by intraplantar application into the left hind paws of anesthetized rats or mice. Arthritis index was assessed by a score system, or the inflammatory response was quantified scintigraphically under a gamma camera by intravenous injection of 500 μCi Na 99m TcO 4 . Kumar et al. (1997) compared the cellular mechanisms involved in the control of collagen II-induced arthritis and experimental autoimmune encephalomyelitis in mice. Ruchatz et al. (1998) studied the role of IL-15 in development of antigen-induced immunopathology in collagen-induced arthritis in DBA/1 mice. A soluble fragment of IL-15 receptor profoundly suppressed the symptoms of collageninduced arthritis. Joosten et al. (1999) immunized male DBA-1 mice with 100 μg bovine type II collagen in CFA enriched with Mycobacterium tuberculosis H37Ra (4 mg/ml) at the base of the tail. The mice were boosted i.p. with 100 μg collagen dissolved in saline. After disease onset on day 28, the mice were treated either with dimerically linked PEGylated soluble p55 TNFR1 receptor or with purified rabbit anti-murine IL-1α and anti IL-1β. IL-1αβ blockade prevented cartilage and bone destruction, whereas TNF-α blockade only ameliorated joint inflammation.

Using a similar protocol, Plater-Zyberg et al. (2001) found a therapeutic effect of neutralizing endogenous IL-18 activity in the collageninduced model of arthritis and Lubberts et al. (2004) after treatment with a neutralizing anti-murine interleukin-17 antibody. Cuzzocrea et al. (2003) found a reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of PPARγ. McIntyre et al. (2003) reported that a highly selective inhibitor of IκB kinase blocked both inflammation and destruction in collagen-induced arthritis in mice. Chen et al. (2003) tested orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs using collagen-induced arthritis in male DBA/1 J mice. Nakae et al. (2002 Nakae et al. ( , 2003 generated IL-17deficient mice and found a suppression of collagen-induced arthritis. Podolin et al. (2005) described attenuation of murine collagen-induced arthritis by a selective small-molecule inhibitor of IκB kinase 2, occurring via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. Kuno et al. (2006) reported anti-inflammatory activity of a non-nucleoside adenosine deaminase inhibitor in mice. Hegen et al. (2008) , Bevaart et al. (2010) , Bolon et al. (2011) , and Roy and Ghosh (2013) reviewed the utility of animal models in arthritis and their suitability for therapeutic target evaluation and correlation with clinical treatment of human rheumatoid arthritis. Many compounds have been evaluated in collagen-induced arthritis including inhibitors of the Bruton's tyrosine kinase (Liu et al. 2011) , inhibitors of Sphingosine-1-phosphate (Fujii et al. 2012) , and agonists of the nicotinic alpha7 receptor . Consistent with this finding, the role of the cholinergic pathway as an anti-inflammatory mechanism has been explored in this model (Levine et al. 2014) . Furthermore, technological advances for imaging inflammation and monitoring therapeutic responses have been developed (Balducci et al. 2012; Sevilla et al. 2015) , which may help progress the discovery and development of new drugs, where differentiation from drugs currently in clinical practice is mandated. 

Purpose and Rationale Glant et al. (1987 Glant et al. ( , 1992 , Mikecz et al. (1987 Mikecz et al. ( , 1990 , and Poole (1989) described a proteoglycan-induced progressive arthritis and spondylitis in BALB/c mice as an animal model displaying similarities to human rheumatoid arthritis and ankylosing spondylitis as indicated by clinical assessments, immunological parameters, and histopathological studies of diarthrodial joints and spine.

High buoyant density cartilage proteoglycans are prepared from fetal and adult human, canine or bovine articular cartilages, as well as 1-week-old mouse epiphyseal cartilage. Fetal human articular cartilage proteoglycan digested with chondroitinase ABC (Hascall and Heinegård 1974 ) is used to induce arthritis in female BALB/c mice. The mice are sensitized by intraperitoneal injection of 100 μg of chondroitinase ABC-treated proteoglycan in 100 μl of phosphatebuffered saline, pH 7.2, and in Freund's complete adjuvant in a 1:1 emulsion. They are reinjected twice more with the antigen in incomplete Freund's adjuvant after 1 and 3 weeks. All BALB/c mice immunized with human articular cartilage proteoglycan develop arthritis in diarthrodial joints after the third antigen injection. Sera from mice with progressive polyarthritis are tested for antibodies to arthritogenic proteoglycans during weeks 12-18 of immunization. The limbs of all mice are examined daily to record clinical arthritic changes. Swelling and redness, as the first symptoms of arthritis, and the thickness (diameter) of the knee, ankle (intermalleolar diameter), wrist, and the dorsovolar thickness of the paw are recorded three times a week. The most objective joint diameter is the intermalleolar one. The animals are treated with test drug or vehicle for 12 weeks and serum samples taken by retroorbital puncture for determination of antibodies to proteoglycans. Seven weeks later, the mice are sacrificed, and limbs, tails, and lumbar spine are fixed, decalcified, and embedded in paraffin for histological examination.

Mean values of intermalleolar diameter and antibody titers of treated and non-treated animals are compared by nonparametric statistics.

Stimpson and Schwab (1989) described a chronic remittent erosive arthritis in rats induced by bacterial peptidoglycan-polysaccharide structures. Glant et al. (2011) extended this model to generate a model based on recombinant human gly-can1 containing T cell epitopes suspected of being arthritogenic. Delemarre et al. (2014) explored the efficacy of autologous bone marrow transplantation in this model showing a stabilization of arthritis scores, and Swart et al. (2014) showed that mesenchymal stem therapy provided by either the intra-articular or intraperitoneal route may suppress proteoglycan-induced arthritis in a murine model. 

Purpose and Rationale The mineral oil 2,6,10,14-tetramethylpentadecane (known as pristane) induces a chronic inflammatory arthritis in mice after intraperitoneal injection (Potter and Wax 1981; Hopkins et al. 1984; Wooley et al. 1989; Chapdelaine et al. 1991; Wooley and Whalen 1991; Levitt et al. 1992; Abe et al. 1995; Thompson et al. 1998; Wooley et al. 1998; Vigar et al. 2000) . The immunological involvement in the pathogenesis of pristaneinduced arthritis was studied by several authors (Bedwell et al. 1987; Thompson et al. 1990; Ghoraishian et al. 1993; Nishikaku et al. 1994; Vingsbo et al. 1996; Stasiuk et al. 1997; Morgan et al. 2004 ). Moreover, the genetic basis for the susceptibility to pristane-induced arthritis was studied (Lu et al. 2002; Olofsson et al. 2003; Brenner et al. 2005; Jensen et al. 2006 ). Not only in mice but also in rats arthritis could be induced by pristane injections (Vingsbo et al. 1996; Zheng et al. 2002 Zheng et al. , 2003 Webster et al. 2003; Holmberg et al. 2006 ). Patten et al. (2004) characterized the model of pristine-induced arthritis (PIA) in mice by studying the response to antirheumatic agents, expression of joint cytokines, and immunopathology.

Induction and Characterization of PIA Male DBA/101aHsd mice were placed under isoflurane anesthesia and injected intraperitoneally with 0.5 ml of pristane (Sigma-Aldrich, Poole, UK), and an identical booster injection was given 7 weeks thereafter. The severity of arthritis was graded visually by assessing the level of swelling in each paw, including the tarsus (ankle) or carpus (wrist) joints. The following scoring system was used: 0.5 = swelling of toes only or very slight ankle/wrist swelling; 1 = slight swelling of paw; 2 = moderate swelling of paw; 3 = marked swelling of paw; and 4 = substantial swelling of paw. Thus, the maximum total score per animal was 16. All batches also contained animals that were not treated with pristane, and these served as comparators for all studies undertaken.

Mice were observed for paw or toe swelling in a time-course study lasting up to 180 days after the first pristane injection. After study termination, the initially swollen hind paws were obtained for histologic assessment and allocated to different study groups according to the duration of swelling. The remaining three paws of each animal were used in cytokine studies.

The effects of administration of established and novel antirheumatic compounds were assessed using a therapeutic dosing schedule. Separate batches of mice for each drug study were monitored weekly for the development of swollen paws from day 80 after the first injection of pristane. Mice were included in the drug studies only if they developed a score of !1 in a hind paw on two consecutive weekly observations between day 120 and day 134 after the first injection of pristane (n = 7-13 per treatment group). At study termination, paws were obtained for histologic and cytokine assessments, normally at 1 h after the final drug administration.

All orally administered treatments were undertaken by gavage. Prednisolone was suspended in 0.5 % methylcellulose and administered orally once daily at a dose of 2 mg/kg. Methotrexate was dissolved in physiologic saline and administered intraperitoneally three times per week at a dose of 9 mg/kg. Indomethacin and diclofenac were suspended in 1 % methylcellulose and given orally once daily at doses of 3 mg/kg and 2 mg/kg, respectively. Celecoxib was suspended in a solution of 66 % polyethylene glycol, 33 % water, and 1 % dimethyl sulfoxide and was administered orally twice daily at a dose of 30 mg/kg. Etanercept was dissolved in the supplied vehicle according to the instructions of the manufacturer and diluted using physiologic saline and was administered intraperitoneally three times per week at doses of 300 μg and 100 μg per mouse. Murine sTNFR, consisting of two murine p75 receptors fused to murine IgG2a, was dissolved in physiologic saline and administered intraperitoneally three times per week at doses of 300 μg and 100 μg per mouse. The selective p38 MAPK inhibitor SB242235 (synthesized at the US GSK Research Center) was suspended in 0.5 % tragacanth and 0.03 M hydrochloric acid and given orally twice daily at doses of 30 mg/kg and 15 mg/kg.

The levels of mRNA and protein for the proinflammatory cytokines TNFα, IL-1β, and IL-6 were measured in disaggregated joints by TaqMan real-time reverse transcriptionpolymerase chain reaction (PCR) and enzymelinked immunosorbent assays (ELISAs), respectively. At study termination and, in the drug studies, 1 h after the final drug treatment administration, the primary ankle joint was removed for histology, and the remaining paws were removed and snap-frozen in liquid nitrogen (six to eight mice per group). For cytokine assessment, the paw showing the highest score for swelling was selected with the proviso that it had also been swollen at the start of the drug study. If the remaining three paws exhibited no swelling at study termination, then the remaining ankle was selected for assay. Whole paws were frozen and pulverized using a mortar and pestle filled with liquid nitrogen.

For the mRNA studies, total RNA was isolated from homogenized paws using RNeasy Mini Kits (Qiagen, Crawley, UK). Samples were treated with 10 units of RNase-free DNase (Qiagen) for 15 min during the RNA isolation process. Reverse transcription of mRNA was carried out using TaqMan reverse transcription reagents in an MJ Research PTC-200 PCR Peltier Thermal Cycler. TaqMan probes and forward and reverse primers for the genes of interest (TNFα, IL-1β, and IL-6) and for housekeeping genes (GAPDH and cyclophilin) were designed with Primer Express TM software (PE Applied Biosystems). Cytokine mRNA expression levels were quantified by TaqMan real-time PCR using the ABI Prism 7900 Sequence Detector System (PE Applied Biosystems).

Blood was withdrawn from all mice before pristane injection and monthly thereafter. Levels of antibodies were determined by ELISA. Plates were coated with 100 μl of coating buffer (0.4 M phosphate buffer, pH 7.6) containing 5 μg of each antigen, at 4 C overnight. The antigens assessed were bovine aggrecan, bovine biglycan, human endoplasmic reticulum molecular chaperone protein, bovine chondroitin sulfate A, bovine chondroitin sulfate B, bovine type I collagen, chick type II collagen, murine type II collagen peptide, bovine decorin, bovine double-stranded DNA, human fibronectin, lupine glucose-6-phosphate isomerase, mycobacterial 65-kDa heat shock protein, murine aggregated IgG, joint extract from normal mice, and joint extract from arthritic mice. Plates were washed three times with 0.05 % Tween 20 in PBS, and nonspecific binding was blocked by 5 % nonfat milk in PBS overnight at 4 C. Serum samples from at least six individual mice per time point were used. Since 1:100 was the dilution determined to produce the optimal response to high-density proteoglycans, mouse serum diluted 1:100 in 5 % milk/PBS was added to each well and incubated overnight at 4 C. Subsequently, the plates were washed six times with 0.05 % Tween 20 in PBS and incubated with alkaline phosphatase-conjugated goat antimouse IgG (Southern Biotechnology Associates, Birmingham, Ala., USA) at 37 C for 1 h. Plates were again washed six times and developed for 40 min in the dark, using p-nitrophenyl phosphate as a chromatogen substrate. The optical density was measured at 405 nm (OD 405nm ) using an ultraviolet max spectrophotometer (Molecular Devices, Sunnyvale, Calif., USA). To ensure uniformity of the assay, negative control sera obtained prior to blood withdrawal and a standard mouse anti-type II collagen antiserum were titered on each plate. Antibody binding was expressed as the OD 405nm in units, blanked against control.

Spleens were excised and immediately immersed in PBS. Tissue was mechanically disrupted to release cells, which were suspended in 10 ml of sterile PBS and centrifuged for 10 min at 1,500 rpm. Prior to resuspension in medium, red blood cells were removed from the spleen preparations by adding distilled water for 10 s and then adding PBS. Spleen cells were then counted using a hemocytometer and washed and resuspended in RPMI at a final concentration of 2.5 Â 10 6 /ml.

Next, 100 μl of spleen cell aliquots (2.5 Â 10 6 / ml) was transferred to 96-well plates with 50 μg/ ml of each antigen (aggrecan, biglycan, chondroitin sulfate A, chondroitin sulfate B, type I collagen, type II collagen, type II collagen peptide, decorin, fibronectin, and heat shock protein; all were derived from the same species as described for the serum antibody studies) in complete RPMI 1640 medium. Cells were incubated for 72 h at 37 C in the presence of antigen. Then 20 μl of MTT solution (a mitochondrial enzyme substrate) was added to each well (5 mg/ml). After a 6-h incubation, the culture supernatant was discarded, and 200 μl of 10 % sodium dodecyl sulfate solution was added to each well. After incubation at 37 C overnight, the OD 590nm was read by microplate photospectrometer (Molecular Devices). The mean OD values were recorded for each cell sample as a measure of antigen stimulation. Antigen-specific responses were calculated as follows: (OD 590nm [stimulated culture]) -(OD 590nm [spontaneous proliferation culture]).

In all studies, the primary ankle joint that was swollen at the beginning of the time-course study or drug study was excised and fixed in 10 % neutral buffered formalin. The tissues were decalcified with formic acid and embedded in paraffin blocks. Sections (4-7 μm) were cut along a longitudinal axis, mounted, and stained with hematoxylin and eosin or toluidine blue, and representative slides for each animal were assessed. The following features were scored in six to ten animals per group: inflammatory exudate, neutrophil and mononuclear cell infiltration, bone resorption, and synovial hyperplasia. For drug studies, the effects of the agents on the pristane-induced pathologic condition were scored as follows: + = mild inhibition of pathologic features, ++ = moderate inhibition of pathologic features, and +++ = marked inhibition of pathologic features.

Graphic and tabular data are expressed as the mean AE SEM. Statistical significance was tested by application of the Kruskal-Wallis test for clinical scores and by analysis of variance followed by Dunnett's test for the cytokine mRNA and protein time-course results. Antibody and cell proliferation studies were analyzed using the least-squares significant difference post hoc test. Brenner et al. (2006) published thermal signature analysis as a novel method for evaluating inflammatory arthritis activity using rats with Freund's adjuvant-induced monoarthritis and pristaneinduced arthritis. The thermal imaging system employs a platinum silicide 256  256 pixel detector array filtered to be sensitive to infrared radiation at a wavelength of 3-5 μm. Lange et al. (2005) investigated the mode of action of methotrexate in different models for rheumatic arthritis, such as fibroblast-induced arthritis in SCID mice, collagen-induced arthritis and anti-collagen II antibody-induced arthritis in rats, and pristane-induced arthritis in DA rats, and models of multiple sclerosis, such as experimental autoimmune encephalomyelitis in (Balb/c  B10.Q) F1 and B10.Q mice.

Pristane induces lupus-like kidney and pulmonary disease in mice (Satoh et al. 1995; Richards et al. 1998; Lin et al. 2004; Chae et al. 2006) . De Franco et al. (2014) used the pristaneinduced arthritis model to dissect genetic determinants for high inflammation susceptibility and demonstrate the involvement of loci interaction with the Slc11a1 gene. Thompson SJ (1993) Comparison between the protective effects of mycobacterial 65-kD heat shock protein and ovomucoid in pristane-induced arthritis. 

Purpose and Rationale Streptococcal cell wall (SCW)-induced arthritis is a chronic and erosive polyarthritis which may be induced in susceptible Lewis rats by a single injection of a sterile, aqueous suspension of SCW via the intraperitoneal route of administration (Cromartie et al. 1977) . The model has been used to study the efficacy of a number of experimental drugs which include the immunosuppressant cyclosporine A ); antibodies to IL-4, IL-10, interferonγ, and monocyte chemotactic protein-1 Schimmer et al. 1998) ; the phosphodiesterase inhibitor rolipram (Laemont et al. 1999) ; the bisphosphonate clodronate (Richards et al. 2001) ; N-butyryl glucosamine (Wang et al. 2007) ; an inhibitor of the purinoreceptor P2X 7 (McInnes et al. 2014) ; and the TNF-a inhibitor etanercept (Chakravathy et al. 2014) .

Lewis rats, typically 120-150 g at the start of the study, receive an injection into the ankle joint of SCW (Lee Laboratories, Grayson, GA, USA). Susceptible animals can be identified by intraarticular injection of SCW (5 μg) into the ankle joint up to day 21 prior to any therapeutic intervention, which may reflect an acute phase of arthritis induction. The chronic, reactivation phase of the study, during which therapeutic intervention is typically investigated, is achieved by intravenous injection of SCW (100-200 μg). Studies normally run for 6-7 days post intravenous injection of SCW but may run for up to 30 days; animals are sacrificed prior to and after intravenous challenge for blood analysis and ankle joint assessment.

Disease severity is typically assessed using the following criteria: 1. A direct measurement of ankle swelling and mechanical hyperalgesia by von Frey threshold using nylon filaments 2. Assessment of histopathological measures which typically include synovitis, inflammation of synovial sub-lining, chondronecrosis, and subchondral bone resorption 3. Radiographical assessment of joint structure It is also common practice to take blood samples for analysis of biomarkers and drug pharmacokinetics. Rioja et al. (2005) conducted an extensive analysis of the gene expression profile in response to SCW-induced arthritis. Kuiper et al. (1998) used a single intravenous injection of SCw (25 μg) and assessed the effects of TNF-α and IL-1β blockade by administration of anti-cytokine antibodies 1 h prior to arthritis induction. Wang et al. (2007) induced arthritis by a single intraperitoneal injection of SCW (15 μg/g weight of rat) and studied the disease-modifying effects of N-butyryl glucosamine commencing the day after SCW injection. 

Purpose and Rationale Immunization of rats or mice with porcine thyroglobulin results in thyroiditis (Vladutiu and Rose 1971; Vladutiu 1983; McGregor et al. 1983; Hassman et al. 1985; Salamero et al. 1987; Fournier et al. 1990 ).

Crude porcine thyroglobulin (PTg) solution is emulsified in complete Freund's adjuvant in a 1:1 ratio. Female mice (6-8 weeks old) are primed with 50 μg PTg given s.c. into four or five sites of injection and are boosted 14 days later with the same dose of PTg (s.c.) emulsified in incomplete Freund's adjutant. The test compounds are administered from day 0 (at priming) until day 21. Mice are bled on day 21 and on day 28 after priming. The sera are tested for the levels of anti-PTg antibodies using an enzyme-linked immunosorbent assay (ELISA). On day 28, the animals are sacrificed and the thyroid glands prepared. Fivemicrometer-thick sections are stained with Masson-Goldner's trichrome solution.

The histological severity of experimental autoimmune thyroiditis is graded as a function of mononuclear cell thyroid infiltration indices:

1. Interstitial accumulation of inflammatory cells distributed between two or more follicles 2. One or two foci of inflammatory cells reaching at least the size of one follicle 3. 10-40 % of the thyroid replaced by inflammatory cells 4. More than 40 % of the thyroid replaced by inflammatory cells

Mean values of treated animals are compared with controls. Castagliola et al. (1994) induced autoimmune thyroid disease in BALB/c mice by immunizing with the extracellular domain of the human TSH receptor expressed as a maltose-binding protein fusion in bacteria. This type of thyroiditis could be transferred to naive BALB/c and NOD mice (Castagliola et al. 1996) . Green et al. (1995) described a spontaneous model of autoimmune thyroiditis in MRL-lpr/ lpr mice.

Furthermore, Green et al. (1996) induced thyroiditis in Lewis rats by immunization with thyroid extract and thyroglobulin. A reduction of the gap junction proteins connexin 43, connexin 32, and connexin 26 was found in diseased thyroid tissue. Wang et al. (2014) showed that overexpression of the human BH3 interacting-domain death agonist (BID) in the thyroids of transgenic mice may increase their sensitivity to iodine-induced autoimmune thyroiditis, noting that BID expression alone is not sufficient to induce thyroiditis. (2014) Overexpression of BID in thyroids of transgenic mice increases sensitivity to iodineinduce autoimmune thyroiditis. J Transl Med 12:180

The effects of immunosuppressant drugs can be studied in the murine model of coxsackievirus B3 myocarditis.

Three-week-old male BALB/c mice are kept for 7 days before the experiment in a single, selfcontained animal isolation unit to exclude pre-diseased animals. They are maintained in disposable, filter-topped cages and handled with gloves by gowned and masked personnel. The intraperitoneal route is used for injection of virus in a 0.5 ml volume. The CVB3 virus strain is grown on either Hep-2 or VERO cells, aliquoted, and maintained at À70 C until use. At the time of infection, seed virus is grown on either VERO or LLC-MK-2 cells with Dulbecco's modified Eagle medium, 12 % fetal calf serum, and gentamicin. Virus is harvested and adjusted to an inoculum of 1.75 Â 10 7 plaque-forming units/0.5 ml RPM-1640. The test drugs are given subcutaneously daily for 8 days. On day 8, the animals are sacrificed, the hearts rapidly removed, and divided into two equal cross sections. The basal portion is snap frozen for isolation of virus and determination of drug level. The apical portion is fixed in 10 % formalin, dehydrated, and embedded in paraffin. Five-mm sections are stained with hematoxylin-eosin and Masson's trichrome stains. The bases of the individual hearts are minced with a sterile scalpel, suspended in 1 ml RPMI-1640, and homogenized in a glass tissue grinder. The suspension is centrifuged at 8,000 g for 10 min at 4 C. Supernatants are harvested and frozen at À70 C until assay. Serial tenfold dilutions of heart homogenates in minimum essential medium are layered on confluent, 72-h-old VERO cells that had been grown in 96-well microtiter plates. Monolayers are checked daily for 7 days for presence or absence of virus and rate of cell destruction.

The slides are examined by two observers blinded to the slide code, and inflammation and necrosis are quantitated. Lane et al. (1991) showed that lipopolysaccharides promote CB3-induced myocarditis in otherwise resistant B10. A mice. Beisel et al. (1991) identified a putative shared epitope between coxsackievirus B4 and mouse alpha cardiac myosin heavy chain. Gauntt et al. (1993) found that epitopes shared between coxsackievirus B3 and normal heart tissue contribute to CVB3-induced myocarditis in mice. Xu et al. (2004) used the murine model to deliver a chitosan-DNA vaccine and showed protection against acute CVB3 challenge. Park et al. (2009) and Yue et al. (2009) further explored approaches supportive of potential immunotherapeutics in this model using pancreatitis as an additional endpoint (Park et al. 2009 ). The model has also been used to investigate the innate immune response as a predictor for the progression of cardiovascular disease and heart failure in male mice (Onyimba et al. 2011) and to better understand the efficacy of further immunotherapeutic approaches where oral administration of interferon-α2b-transformed Bifidobacterium longum was shown to protect animals from CVB3-induced myocarditis (Yu et al. 2011) .

A number of other agents have been tested in this model and include galectin-9 which ameliorated CVB3-induced myocarditis (Lv et al. 2011 ), IL-17 which was found to be protective (Xie et al. 2012) , and the micro-RNA miR-21 which alleviated CVB3-induced myocarditis . A comparison of the effects of ivabradine and carvedilol showed an expected effect on heart rate reduction and a potential anti-inflammatory effect in the CVB3-induced myocarditis model.

Instead of coxsackievirus B3, Monrad et al. (1986) used encephalomyocarditis virus to induce experimental myocarditis in mice. 

Purpose and Rationale Pummerer et al. (1991) , Inomata et al. (1995) , Suzuki (1995) , and Dimitrijevic et al. (1998) described autoimmune myocarditis in rats induced by porcine cardiac myosin.

Male Sprague-Dawley or Lewis rats at the age of 8-10 weeks are immunized with porcine cardiac myosin either purchased from Sigma (St. Louis, MO, USA) or prepared from the ventricular muscle of porcine hearts according to Murakami et al. (1976) . The cardiac myosin fraction is dissolved in phosphate buffer at a concentration of 10 mg/ml. The antigen solution is emulsified with equal volume of complete Freund's adjuvant supplemented with heat-killed mycobacterium tuberculosis. Rats are injected subcutaneously into the foot pad with an immunizing dose of 5 mg of antigen in complete Freund's adjuvant/ kg of body weight. Rats are injected intraperitoneally with test compounds either from day 0 to 6 (early treatment group) or from day 14 to 20 (late treatment group). Immunized rats are sacrificed on days 8, 16, 21, and 34, respectively. Disease course and severity are analyzed by macroscopic findings of the hearts and heart weight/bodyweight ratio as well as by histological and immunohistochemical analysis. Macroscopic findings are scored as follows: 0, normal finding; 1, presence of focal discolored area on the surface; and 2, presence of diffuse discolored areas .

The hearts are removed and weighted immediately after the rats are sacrificed, fixed in 10 % buffered formalin, and embedded in paraffin. Serial section (5 μm in thickness) is stained with hematoxylin-eosin. The severity of myocarditis is determined according to the following scoring system: 0, no inflammation; 1, histological cross section infiltrated up to 5 %; 2, 5-10 % infiltrates/ section; 3, 10-20 % infiltrates/section; greater than 20 % infiltrates/section.

For immunohistochemical staining, heart samples are embedded in OCT compound (Miles, Elkhart, IN) and rapidly frozen. Cryostat sections are cut sequentially at 7 μm in thickness, mounted on glass slides, and prepared for immunoperoxidase staining. Sections are fixed in cold acetone for 10 min and extensively washed in 0.1 M Tris buffer solution, pH 7.6. Murine monoclonal antibodies specific for different rat molecules are added at appropriate concentrations. After incubation at 4 C overnight and further buffer washes, the sections are incubated with peroxidase-conjugated anti-mouse immunoglobulins for 60 min. Peroxidase reaction is visualized with 0.05 % diaminobenzidine in 0.01 % H 2 O 2 for 7-8 min. The color development is stopped by washing slides in running water. All samples are lightly counterstained with hematoxylin, mounted in gelatin/glycerol medium, and assessed by light microscopy.

Macroscopic and microscopic scores are expressed as mean values. Body weights, heart weights, and heart weight/body weight ratio are expressed as mean AE SD. Student's t-test for paired samples is used for comparison data within groups in reference to time, while two-sample t-test is used for comparison data between groups. Koyama et al. (1995) immunized Lewis rats with human cardiac myosin suspended in complete Freund's adjuvant and induced severe active myocarditis with acute and chronic heart failure. The baseline left ventricular pressure was significantly lower in the chronic phase group, and peak dP/dt was significantly lower in both the acute phase group and the chronic phase group than in the respective controls. The animal model was recommended to study both acute heart failure related to acute myocarditis and chronic heart failure due to diffuse myocardial fibrosis. Neu et al. (1990 Neu and Ploier 1991; Penninger et al. 1993 ) induced severe autoimmune myocarditis in some mouse strains by immunization with cardiac myosin in complete Freund's adjuvant. Wahed et al. (2005) used the method of immunization with porcine cardiac myosin to test the effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy. 

Purpose and Rationale Experimental allergic encephalomyelitis was first produced in laboratory animals by Rivers et al. in 1933. This pathological model is an immunologic disease arising from a delayed hypersensitivity reaction to nervous tissue. In many respects, the model resembles autoimmune diseases, especially demyelinating diseases, in man (Constantinescu et al. 2011) , and the utility of animal models as for drug discovery and development for neurological diseases especially multiple sclerosis (MS) has been extensively reviewed (Croxford et al. 2011; Denic et al. 2011; Pachner 2011; Singhal and Srivastava 2012; Tian et al. 2013 ). The method is used for evaluation of immunosuppressive properties of drugs (Warford and Robertson 2011; Dasgupta et al. 2011; Paris et al. 2013; Mondal and Pahan 2015) .

Preparation of the encephalitogen: 3 g of spinal cord from guinea pigs or rats is homogenized with 7.5 ml bidistilled water, 3.8 ml phenol, and 7.5 ml complete Freund's adjuvant under cooling. Groups of 6-12 male Wistar-Lewis rats with an initial body weight of 130-200 g are used. On day 0, experimental allergic encephalomyelitis is induced by subplantar injection of 0.1 ml of the encephalitogen into the left hind paw. An equal volume of Bordetella pertussis vaccine concentrate (200 Â 10 9 organisms/ml) is injected into the same foot. From days 1-2, the animals receive the test compound or vehicle only or the standard drug by oral administration once a day. Body weights of the animals are recorded every second day. The clinical signs of experimental allergic encephalomyelitis consist of ataxia or paresis, i. e., grossly irregular gait and weakness of one or both hind legs followed by flaccid paralysis of the hindquarters, urinary incontinence, fecal impaction, and abdominal wall flaccidity. Animals showing one of these clinical signs are considered positive for the purpose of evaluation.

Starting from day 7, the severity of clinical signs and mortality are determined daily and scored according to the following scheme: Score Per 20 g loss of weight 1 Paralysis of the tail 1 Paralysis of the hind paw 3 Complete paralysis 5 Death 6

The delay of onset of the paralytic symptoms is determined. The total score per day is recorded for treated and control groups. On the day of maximal clinical symptoms occurring among control animals, the total score of the treated groups is compared to the total score of the control group. The percentage change is evaluated. Doses of 0.5 mg/kg p.o. methotrexate, 1 mg/kg p.o. hydrocortisone, and 2.5 mg/kg p.o. cyclophosphamide were found to be active, whereas nonsteroidal anti-inflammatory compounds were inactive.

The model of experimental allergic encephalomyelitis in rats is suitable to distinguish between immunosuppressive and anti-inflammatory drugs. Experimental autoimmune encephalomyelitis is considered as a rodent model of the autoimmune disease multiple sclerosis (Pearson et al. 1997; Deng et al. 2002) .

The phosphodiesterase inhibitor pentoxifylline was found to prevent induction of experimental autoimmune encephalomyelitis in Lewis rats (Rott et al. 1993) . Martin and Near (1995) studied the protective effect of the interleukin-1 antagonist IL-1ra on experimental allergic encephalomyelitis in Lewis rats.

Experimental autoimmune encephalomyelitis in different strains of mice was described by Heremans et al. (1996) , Glabinski et al. (1997) , and Liblau et al. (1997) . Baker et al. (1990 Baker et al. ( , 1991 Baker et al. ( , 2000 induced experimental allergic encephalomyelitis in Biozzi AB/H mice by sensitization with 1 mg of mouse spinal cord homogenate emulsified in Freund's complete adjuvant on days 0 and 7. The disease is characterized by relapsing-remitting episodes similar to multiple sclerosis in human beings. Biozzi AB/H mice also develop spasticity and tremor which can be antagonized by cannabinoids.

A chronic relapsing-remitting form of experimental autoimmune encephalomyelitis was induced in the common marmoset Callithrix jacchus following a single immunization with human white matter by Massacesi et al. (1995) and Genain and Hauser (1997) and recommended as a new model for multiple sclerosis. This model has been used for histopathological characterization of magnetic resonance imaging-detectable white matter lesions in a primate model of multiple sclerosis by 't Hart et al. (1998, 2004) .

Experimental allergic neuritis in several animal species has been described by Adams (1955, 1956) ; King et al. (1983); McCombe et al. (1990) , and Nakayasu et al. (1990) . This disorder has been considered to show similarities to the Guillain-Barré syndrome in man. The demyelinating process initiated by the injected antigens is a lymphocytemediated reaction in which activated macrophages strip myelin off the axons. Hartung et al. (1987) described the adoptive transfer experimental autoimmune neuritis in Lewis rats by injection of P2-reactive T lymphocyte cell lines. Mix et al. (1992) studied the effect of stilbenetype anion channel blockers on the immune response during experimental allergic neuritis induced by bovine peripheral myelin. Kojima et al. (1994) investigated the pathogenic potential of autoimmune T cell responses to nonmyelin autoantigens in the Lewis rat using the astrocyte-derived calcium-binding protein S100β as a model nonmyelin autoantigen. In contrast to the experimental autoimmune encephalomyelitis induced by the adoptive transfer of myelin basic protein-specific T line cells, S100βspecific T cell transfer induced intense inflammation not only in the spinal cord but also throughout the entire CNS and also in the uvea and retina of the eye. Gautam et al. (1992) reported that a polyalanine peptide with only five native basic protein residues induces autoimmune encephalomyelitis in mice. This peptide, called myelin basic protein (MBP) Ac1-11, has been used by several authors for further studies on experimental autoimmune encephalomyelitis (Ratts et al. 1999; Matejuk et al. 2003) . Pearson et al. (1997) reported the induction of a heterogeneous T cell receptor repertoire in (PL/JXSJL/J) F2 mice by myelin basic protein peptide Ac1-11 and its analogue Ac1-11[4A]. Deng et al. (2002) found that expression of the tyrosine phosphatase Src homology 2 domaincontaining protein tyrosine phosphatase 1 determines the T cell activation threshold and severity of experimental autoimmune encephalomyelitis. Maron et al. (2002) investigated the immunological properties of Cop1 (glatiramer acetate) to determine the degree to which its effects were antigen specific using myelin basic protein T cell receptor transgenic mice. Immunization of these mice fed glatiramer acetate, myelin basic protein, or MBP Ac1-11 resulted in decreased proliferation and IL-2, IL-6, and IFN-γ production and increased secretion of IL-10 and TGF-β in glatiramer acetate-fed animals. Gilgun-Sherki et al. (2003) reported that riluzole suppresses myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in mice. Pollak et al. (2003) studied the experimental allergic encephalitis-associated behavioral syndrome and the modulation by anti-inflammatory treatments. Diab et al. (2004) found that ligands for the PPAR-γ and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. Duckers et al. (1997) studied the effect of a neurotropic treatment on cortical lesion development in experimental allergic encephalomyelitis in rats by longitudinal in vivo magnetic resonance imaging methods. Acute Graft-Versus-Host Disease (GVHD) in Rats

The intravenous injection of a mixture of parental splenocytes into healthy inbred F 1 -rats results in graft-versus-host (GVH)-induced immune abnormalities. This is due to T lymphocytes in the donor inoculum that recognize the major histocompatibility alloantigens expressed by the F 1 -animals. The host F 1 T cells are genetically unable to recognize antigens of the parental donor as foreign; thus, the response involves only donor recognition of host and not host recognition of donor. The ensuing immune abnormalities lead to clinical symptoms of an acute, lethal GVH-disease (GVHD), i.e., profound immunodeficiency, anemia, hypogammaglobulinemia, and runting.

Three-to 4-month-old male F 1 -hybrid rats of the inbred strains Lewis (Rt-1 l) and Brown Norway (BN, Rt-1n) (Zentralinstitut f€ ur Versuchstierkunde, Hannover, Germany) are used as hosts for cell grafts from the Lewis parental strain. The bone marrow cells are obtained by flushing hind femur bone shafts with culture medium. These cells are then pooled together with spleen cells (ratio 2 bones/1 spleen). The cell viability, determined by trypan exclusion, has to be more than 90 %. Each recipient is injected with about 40 Â 10 7 cells in a 1.5 ml suspension volume. The route of injection is the penis vein, allowing an optimal control of correct intravenous application.

For this experiment, two groups of 6 F 1 -hybrids each are injected with the abovementioned bone marrow/spleen cell suspension. One group receives the test drug orally and daily until the end of the experiment, homogeneously suspended in 1 % carboxymethylcellulose (CMC) solution.

The other group receives CMC alone and, thus, serving as the GVHD control group. The experiment is terminated 2 weeks after disease induction, i.e., 1 week after the first appearance of GVHD symptoms. All animals are sacrificed and clinical aspects documented; spleens weighed; histology of the skin, liver, spleen, and lymph nodes performed; and organs photographed.

In this experiment, rats are separated into four groups and treatment begins with the first sign of GVHD symptoms (beginning of the second week). Because of the expected, greater therapeutic difficulty, the daily dose of the test drug has to be doubled, again for 2 weeks duration. The experiment is terminated either by sacrificing those rats that are too sick to be able to move around the cage or at the end of the 4-week observation period, regardless of the clinical condition of the animals. The clinical-chemical parameters are determined by routine procedures conducted with a Hitachi autotechnicon.

The tested parameters of therapeutic success or disease, respectively, are survival rate (%), spleen weight (g), and body weight (g) as well as clinicalchemical parameters (bilirubin, alkaline phosphatase, creatinine, white cell count) after 2 and 3 weeks. Gelpi et al. (1994) established a chronic graftversus-host disease in (C5BL/10  DBA/2) F 1 mice with an injection of lymphoid cells from the parent DBA/2 strain. Most of the animals developed antibodies against transfer RNA/protein particles. Mosier et al. (1988) reported transplantation of human peripheral blood lymphocytes (PBL) into severe combined immunodeficient (SCID) mice to construct hu-PBL-SCID mice. Kim et al. (1997) suggested these mice for routine immunotoxicity investigations using lymph nodes of intestines as the lymphocyte sources. Ford et al. (1970) and used the popliteal lymph node assay to study the local graft-versus-host reaction. The test is based on the enlargement of the draining popliteal lymph nodes as a result of injecting immunocompetent cells (1  10 8 parental Lewis spleen cells) into the hind foot pad of Lewis  Brown Norway F1 recipients. The reaction is measured at day 6 after challenge as a gain in lymph node weights. Xu et al. (2010) explored the effects of both rapamycin and tacrolimus in the model measuring animal survival after liver transplantation and reporting a differential effect on survival between the two drugs. Xia et al. (2013) investigated the effects of Trichostatin A (TSA) in the rat model of liver transplantation and concluded that TSA did not abrogate acute graft-versus-host disease due to a downregulation of regulatory T cells. Influence on SLE-Like Disorder in MRL/lpr Mice

Systemic lupus erythematosus (SLE) is an autoimmune disease in man that affects multiple body organs and is characterized by the development of certain types of self-antigens. Primarily, the antibodies formed against double-stranded DNA (dsDNA), the most prevalent in this ailment, complex together and, with complement, deposit in the small blood vessels, leading to widespread vasculitis. MRL Mpf lpr/lpr (MRL/lpr) mice spontaneously develop a severe disease with many symptoms very similar to human SLE, i.e., hypergammaglobulinemia and glomerulonephritis (Theofilopoulos and Dixon 1981) . Recent years have seen the development of numerous animal models of skin disease which have assisted the discovery of potential new drugs for clinical testing (Rottman and Willis 2010; Avci et al. 2013 ) which in part have allowed progression of a number of small-molecule candidate drugs Markopoulou and Kyttaris 2013) .

Female MRL/lpr mice (originally from Jackson Laboratories, USA), displaying distinct symptoms of SLE (between 12 and 13 weeks of age), are randomized and divided into groups of 12 animals each. At this age, the animals have already clinical manifestations of the SLE-like illness, as determined by the disease index, but have not yet developed proteinuria. Animals with early symptoms of disease are treated with various drugs, e.g., leflunomide, cyclosporine A, azathioprine, cyclophosphamide, or prednisolone, for 11 weeks, and the survival rate and disease index of these animals are followed for 24 weeks. The disease index and urine protein level are determined once weekly.

The subsequent clinical parameters are taken into consideration:

1. Ears: reddening of the skin, deterioration of the pinna 2. Nose: loss of hair, wasting of the skin 3. Lymph nodes: detection of swollen lymph nodes on any part of the body, especially the neck and extremities 4. Fur: general condition of fur (e.g., shabby, mangy, etc.), loss of hair 5. Skin: inflammation of the skin, scab, and/or granuloma formation 6. Eyes: exophthalmos, deterioration due to inflammation, tumor formation around the eye, swelling of the eyelid with eventual closure of the eye 7. Paws: reddening of the skin, swelling of the paw Evaluation A score for each of the above-described parameters is given according to the severity of the symptoms as follows: Body weight (one point for 5 g difference from week to week)

The determination of the disease index is performed, weekly, by the same individual, but without knowledge of the group being evaluated. The points, for each animal, are registered and the total score, of each group, summarized. The average score for the group is calculated, and significance between the experimental group and the untreated diseased group is determined using the Student's t-test.

Pooled urine is collected from each experimental group and the amount of protein in the urine is calculated.

In addition to a lupus-like syndrome and massive T cell proliferation, MRL-1pr/1pr (MRL/1) mice develop an arthritic process very similar serologically and histologically to human rheumatoid arthritis. Boissier et al. (1989) found that in these animals, mouse type II collagen is antigenic, but not arthritogenic. Holmdahl et al. (1991) studied the involvement of macrophages and dendritic cells in synovial inflammation of collagen-induced arthritis in DBA/1 mice and spontaneous arthritis in MRL/lpr mice. Rordorf-Adam et al. (1985) used serum amyloid P component and autoimmune parameters in the assessment of arthritis in MRL/lpr/lpr mice. Furukawa et al. (1996) studied the autoimmune disease-prone genetic background in relation to Fas defect in MRL/lpr mice. Kanno et al. (1992) found spontaneous development of pancreatitis in the MRL/Mp strain of mice. Kusakari et al. (1992) compared hearing acuity and inner ear disorders of MRL/lpr mice with those of BALB/c mice and found a significantly higher auditory brain stem response threshold. They recommended this as a model of sensorineural hearing loss. Bundick and Eady (1992) investigated the effects of an immunosuppressive agent on the development of spontaneous lupus disease in female NZBW F1-hybrid mice. Walker et al. (1996) reported a powerful suppressive effect of testosterone on the autoimmune disease analogous to systemic lupus erythematodes spontaneously developed by F1-hybrids of New Zealand Black (NZB) Â New Zealand White (NZW) mice. A model was developed in which NZB dams carrying NZB/NZW fetuses were treated with testosterone in a dose adequate to masculinize the external genitalia in female fetuses. Zoja et al. (1998) investigated bindarit, a compound devoid of immunosuppressive properties, in NZB/W F1 hybrid mice developing an immune complex glomerulonephritis with proteinuria and progression to renal insufficiency. Kiberd and Stadnyk (1995) studied the role of endogenous interleukin-1 in established lupus nephritis in MRL-lpr/lpr mice by administration of the IL-1 receptor antagonist IL-1ra. Gleichmann et al. (1982) and induced a systemic lupus erythematodes-like disease in mice by abnormal T and B cell cooperation. A chronic graft-versushost reaction with the pathologic symptoms of severe glomerulonephritis is induced in B6D2 (C5Bl/6 Â DBA/2) F1 hybrid mice receiving four i.v. injections (one per week) of 1 Â 10 8 parental lymphoid spleen cells from DBA/2 donors. The inoculation of splenocytes into the BDF1 hybrid mice results in the development of a chronic GvH reaction with lymphoid hyperplasia, autoantibody production, and immune complex glomerulonephritis. Chan et al. (1995) described ocular changes occurring in mice with experimental lupus erythematodes. The ocular disease is characterized by bilateral subacute and chronic inflammation of the eyelids (blepharitis) and hypertrophic meibomian glands. The severity of the ocular changes is strain dependent. The authors recommend this experimental eye disease as an animal model for chronic blepharitis in humans.

The changes of lacrimal and salivary glands found in MRL/lpr mice and other mouse strains with autoimmune disorders were also regarded as model of Sjögren's syndrome in human (Sullivan and Edwards 1997; Toda et al. 1999 ).

The MRL-lpr mouse model has been used to provide cognitive dysfunction in neuropsychiatric systemic lupus erythematosus (Jeltsch-David and Muller 2014), and peptide microarray technology has been developed which may facilitate diagnosis and early detection of CNS-SLE (Williams et al. 2014) .

Several studies have investigated the effects of T cell modulation in the MRL/lpr model (Richard et al. 2013; Shinsuke and Hiroshi 2013) , and the role of peptidylarginine deiminase and NET formation has been investigated in the MRL/lpr model (Knight et al. 2014 ).

An assessment of the value of murine lupus models for translation of findings into the clinic (Bender et al. 2014) has highlighted the individuals' strengths of the various models available. 

Purpose and Rationale Myasthenia gravis is an organ-specific autoimmune disease in man that results in skeletal muscles' weakness. Typically, the sufferer has drooping eyelids, a blank facial expression, and weak, hesitant speech. This is due to the formation of autoantibodies against the nicotinic acetylcholine receptor (AChR). The formation of autoantibodies to acetylcholine's receptor leads to a gradual destruction of the receptors in skeletal muscles that receive nerve impulses and initiate muscle contractions. As a result, affected muscles fail to respond or react only weakly to nerve signals. Experimental myasthenia gravis (EMG) can be induced in rats by injecting them with heterologous AChR or with recombinant α-subunits (two) of the AChR (portion of the AChR to which acetylcholine mainly binds) (Lennon et al. 1991) , and the utility of clinical trials to guide the use of animal models has been recently addressed (Punga et al. 2015) . The animals display symptoms of myasthenia (electrophysiological evidence of altered neuromuscular function) and detectable antireceptor antibodies. The severity of the disease can vary, but most animals display, at the very least, a weakness and fatigability of foot grip. The disease gradually leads to abnormal gait and eventually the inability of the animals to walk or even right themselves.

Female rats of AO strain, 6-10 weeks old, are used. Three groups of rats are included in the experiment:

1. Immunized with acetylcholine receptor (AChR) protein and treated with test drug. 2. Immunized with AChR protein without drug. 3. Nonimmunized, non-treated control rats. The test drug is applied per os daily. First dose is administered on the day of immunization and the last on the day of sacrifice.

AChR protein isolated from Torpedo marmorata is emulsified with complete Freund's adjuvant, and 100 μg/rat is injected intradermally in the hind foot pad. As additional adjuvant, 2.6 Â 10 10 Bordetella pertussis microorganism is administered simultaneously by intramuscular injection in the hind leg.

Anti-AChR-protein antibodies are measured by enzyme-linked immunosorbent assay (ELISA) as described by Norcross et al. (1980) . AChR protein is diluted to a final concentration of 2.5 μg/ml in 0.05 M carbonate buffer, pH 9.6. Two hundred ml of this solution is placed in each well of a microtitration plate (Flow Laboratories Inc.). After an overnight incubation at 4 C, the plates are washed thoroughly with 0.01 M phosphatebuffered saline (PBS) solution containing 0.05 % Tween 20 (Sigma) subsequently referred to as PBS/T. Sera from all groups of rats are serially diluted in PBS/T, and 200 μl is added to each micron well except in the background row (control row) and incubated at 4 C for 2 h. After washing, 200 μl of 1:1,000 diluted peroxidaseconjugated goat anti-rat immunoglobulin (Sera Lab. Sussex, England) in PBS/T is added to the micron wells and incubated for an additional 60 min at 4 C. After plates are washed, 200 μl of substrate-citrate buffer and 0.2 μl of 10 % H 2 O 2 are added and then incubated in the dark at room temperature for 30 min. The reaction is stopped by addition of 50 μl of 2 M H 2 SO 4 and the OD determined by using Titert Multiscan.

Thymic cell suspensions are obtained by mincing tissue and passing it through 80-mm stainless mesh. After being washed three times in PBS, the cells are resuspended in PBS at a cell density of 10 7 viable cells/ml. The cell viability is determined by the trypan blue exclusion test. Erythrocytes are removed by addition of ammonium chloride. Cell staining and flow cytometric analyses are done as described by Itoyama et al. (1989) . Thymocyte subsets expressing CD4 and/or CD8 molecules are defined by staining with monoclonal antibodies obtained from Serotec, Oxford, England: phycoerythrin (PE)-conjugated anti-W3/25 (CD4) and fluorescein isothiocyanate (FITC)-conjugated anti-MRC OX8 (CD8). Two  10 5 -1  10 6 cells suspended in 100 ml of PBS are exposed sequentially for 30 min to FITC-conjugated anti-CD8 and PE-conjugated anti-CD4 monoclonal antibodies. Isotype-matched control monoclonal antibodies are used to prove the specificity of binding. Cell analysis is performed using FACScan flow cytometer from Becton Dickinson. One  10 4 events per sample are analyzed by Consort 30 and Lysis software. All data are collected and displayed on a log scale of increasing green and orange fluorescence intensity. This is presented as two-dimensional contour maps and as percentage of thymocytes by integrating counts in selected areas of the contour plots.

Thymuses of animals of all groups are prepared for light microscopic analysis. For this purpose, thymus tissue is fixed in Carnoy's solution, embedded in paraffin, and 3-5-μm-thin sections are stained with hematoxylin and eosin. Cortex and medulla are analyzed stereologically using the point counting method described by Weible (1963) . Volume density (Vv) of the examined structures is determined by the following equation: Vv = Pi/Pt, where Pi represents the number of points of the examined structure and Pt the total number of points. Vv refers to the volume fraction, i.e., volume of a feature per unit test volume (Tascaland Vaughn-Williams 1981) .

Evaluation EMG is evaluated clinically by daily examination of muscle weakness and scored as follows: + = weakness of grip with fatigability ++ = abnormality of gait +++ = inability to walking and righting Immediately after appearance of clinical signs of EMG, rats are sacrificed, and blood and thymuses are taken for determination of anti-AChR-protein antibodies and histological analysis of thymuses and thymocyte subsets, respectively.

Statistical analysis of data is performed by Student's t-test (data of stereological analysis) and Mann-Whitney U-test (results of flow cytometric analysis of thymocyte subsets).

McIntosh and Drachman (1987) described an in vitro suppressor assay using responder cells from the lymph nodes of Lewis rats immunized sc. with acetylcholine receptors emulsified in complete Freund's adjuvant and suppressor cells from spleens of rats immunized i.p. with acetylcholine receptors absorbed on bentonite. Antibodies were determined after stimulation with acetylcholine receptors from cocultures of responder cells and putative suppressor cells treated previously with an immunosuppressant. Arag and Blalock (1994) developed a method of altering B cell-mediated autoimmune diseases by induction of anti-idiotypic antibodies by immunization with complementary peptides. A peptide encoded by RNA complementary to RNA for the Torpedo acetylcholine receptor main immunogenic region, AChR 67-16, was tested in the Lewis rat model of experimental autoimmune myasthenia gravis. Russell et al. (2012) reported on the testing of CK-2017357 (Tirasemtiv) in rat model of myasthenia gravis and showed as a troponin activator it improved muscle function in this model. Oliveira et al. (2015) describe the role of CD73 in impaired neuromuscular transmission in the EMG model and further describe the potential role of adenosine in the pathophysiology on this neuromuscular disorder. 

Purpose and Rationale Masugi nephritis and other nephritis models of immunological origin in rats have been used for evaluation of immunosuppressive activity (Heymann et al. 1959; Shibata et al. 1966; Ito et al. 1983; Ogawa et al. 1990 Ogawa et al. , 1991 .

Preparation of Rabbit Antiserum Against Rat Glomerular Basement Membrane Glomeruli are separated from the homogenate of rat renal cortex by successive use of three metal sieves (150-, 180-, and 200-mesh) . The basement membrane fraction is obtained by centrifugation and ultrasonic disruption. It is then digested with trypsin, dialyzed, and lyophilized. The resultant substance is employed as antigen. An emulsion of 1 mg of the antigen in 0.2 ml saline with 0.2 ml of complete Freund's adjuvant is injected intracutaneously into white rabbits once a week for 6 weeks. One week later, production of the antibasement membrane antibody is confirmed in guinea pigs by the passive cutaneous anaphylaxis test. The blood is collected from the carotid artery, incubated at 56 C for 30 min to inactivate components of the complement and stored at À20 C until use.

Male Sprague-Dawley rats weighing about 300 g are injected with 0.5 ml of the rabbit antiserum via the tail vein. On the following day, they are further injected subcutaneously with an emulsion (0.25 ml) of physiological saline solution containing 5 mg of rabbit gamma globulin in an identical volume of complete Freund's adjuvant.

The rat antibasement antibody is injected 5 days before the start of administration of the test compound. Before the first dose, urinary total protein is determined and rats with nephritis are so assigned as to provide almost equal distribution of severity of the disease per group. The test compounds are administered orally for 14 days. The urine is collected at 7 and 14 days of treatment. After 14 days, the animals are sacrificed, blood is collected, and the thymus and kidneys are removed. Histopathological and immunohistochemical studies are performed in kidney tissue.

Scores are given for microscopic findings in the following:

• Cell proliferation in glomeruli • PAS-positive granules in the epithelium of glomeruli • Fibrin deposits in Bowman's space • Adhesion to Bowman's capsule Tubuli • Hyaline cast • Dilation of tubuli Scores are also given for immunofluorescence findings for rat IgG, rat C3, and rabbit IgG.

Furthermore, total urinary protein, plasma total cholesterol, plasma fibrinogen, and thymus/body weight ratio are compared between drug-treated animals and controls by statistical means. Lan et al. (1995) investigated the pathogenic role of interleukin-1 in the progression of established rat crescentic glomerulonephritis by administration of the interleukin-1 receptor antagonist IL-1ra. and Thoenes et al. (1987) induced autoimmune tubulointerstitial nephritis in the Brown Norway rat by injection of bovine tubular basement membrane.

Development of a systemic T lymphocytedependent autoimmune syndrome in Brown Norway rats including glomerulonephritis with high proteinuria was induced with mercuric chloride by , Aten et al. (1988) , and Lillevang et al. (1992) . Kokui et al. (1992) induced nephrosis with proteinuria in rats by intraperitoneal injection of puromycin aminonucleoside. Lundstrom et al. (1993) studied the Heymann nephritis antigenic complex using a rat yolk sac carcinoma cell line that expresses glycoprotein 330, the main antigen in this autoimmune disease. Taylor et al. (2009) demonstrated a role for the purinergic P2X7 purinoreceptor in experimental glomerulonephritis showing that mice harboring a knockout for the receptor were renoprotective, further supported by a nonclinical intervention study with A-439079. Smith et al. (2010) investigated the role of spleen tyrosine kinase (SYK) in a rat model of glomerulonephritis with R788 (fostamatinib) and showed reduction of glomerular crescents and improvement in renal function establishing SYK as a target for potential future clinical investigation. Suana et al. (2011) 

Purpose and Rationale Transplantation of allogenic organs to recipients results in rejection of the transplants (Sanchez-Fueyo and Strom 2011). This effect can be suppressed or delayed by immunosuppressive agents, and the role of B cells has been investigated in animal models suggesting a role in mechanisms of transplant tolerance . Various organs are used for allogenic transplantation in animal experiments, such as skin pieces (Schorlemmer et al. 1993) , kidney (Lee 1967; , rat heart, rat small intestine , and corneal buttons . The immunosuppressive activity can be evaluated either by using a major histocompatibility complex variant strain combination or a strong allogenic system, and the advances and limitations of murine models have been recently described (Schroeder and DiPersio 2011) .

For skin transplantation male animals of inbred strains of Fischer (F334), Lewis (LEW), Brown Norway (BN), and Dark Agouti (DA) rats are used. Rat tail skin (donor) is cut into square pieces of 0.5-1.0 cm and transplanted to the tails of recipient rats. Rejection is defined as the day when the skin graft is of red-brown color and hard consistency. As strain combination with a major histocompatibility variant, transplantation from LEW to F334 is performed. Using a strong allogenic system, the high responder DA to LEW donor-recipient combination is used. The immunosuppressive agents, e.g., cyclosporine or leflunomide, are given orally up to 20 days. Ten animals are used for each group.

The mean values of rejection time of treated groups are compared statistically with vehicletreated controls using Student's t-test or the Mann-Whitney U-test.

Schorlemmer and Kurrle (1997) used Lewis (LEW, Rtl*l) rats as receivers and Balb/c mice as donors in a xenotransplantation model of mouseto-rat skin grafts. Rejection was defined as the day when the skin graft turned red-brown and became hard. For quantification of xenospecific IgM and IgG antibody titers, the test sera (dilution 1:10) were incubated with 1 Â 10 6 purified T cells (by sheep anti-mouse Dynabeads, Deutsche Dynal GmbH, Hamburg, Germany) from Balb/c donor spleens for 30 min at 4 C. The cells were washed three times with phosphate-buffered saline (pH 7.2) and then stained for IgG or IgM xenoantibodies; 50 μl of FITC-conjugated goat antibodies, specific for the Fc-portion of rat IgG or specific for the μ-chain of rat IgM, was added. After 30 min at 4 C, the cells were washed twice and analyzed by flow cytometry. Techniques for transplantation of several organs have been elaborated.

For kidney transplantation, male rats, 5-7 months of age, are used as donors and recipients for the orthotopic right kidney transplantation as described by Lee (1967) with a modification of ureter-ureter anastomosis (Thoenes et al. 1974) . Because bilateral nephrectomy is performed at transplantation, animal survival is dependent upon the allograft's function. All rats that do not excrete urine on the first postoperative day are excluded from further studies. As a control concerning long survival, syngenically transplanted rats are maintained up to 300 days. Engelbrecht et al. (1992) described a new rapid technique for renal transplantation in the rat. The method combines a special sleeve anastomotic technique for the renal artery, conventional endto-end anastomosis of the renal vein, and implantation of the ureter into the bladder.

A porcine renal transplant model has been used by . Peters et al. (1993) reviewed the therapeutic potential of tacrolimus in renal and hepatic transplantation.

For studying heart transplantation, heterotopic implantation of hearts from BN to LEW rats is performed (Williams et al. 1993) . The diagnosis of rejection is established once the palpable cardiac allograft impulse ceases. Further studies with rat cardiac allografts have been performed by Hancock et al. (1990) . The Fischer 344 rat (donor)/Long Evans rat (recipient) combination was used by Kahn et al. (1991) . Walpoth et al. (1993) used magnetic resonance spectroscopy for assessing myocardial rejection in the transplanted rat heart. Shiraishi et al. (1995) evaluated the effectiveness of the interleukin-1 receptor antagonist IL-1ra in the immune and inflammatory responses to rat heart allografts.

Cardiac transplantation between inbred rat strains that differ for weak histocompatibility antigens is associated with the development of arteriosclerosis in arteries of the donor graft myocardium Adams et al. 1992) .

A heterotopic rat heart transplant model and the influence of infection were described by Kobayashi et al. (1993) .

The hamster to rat cardiac xenograft model has been used by several authors (de Masi et al. 1990; Steinbr€ uchel et al. 1991; van den Bogaerde et al. 1991; Woo et al. 1993; Fujino et al. 1994; Schuurman et al. 1994 ). The hearts from Syrian hamsters were implanted heterotopically in male Lewis rats, with anastomoses between the infrarenal abdominal aorta and inferior vena cava of the recipient and the donor aorta and right pulmonary artery, respectively.

Primate cardiac xenografts were performed by McManus et al. (1993) using cynomolgus monkeys (Macaca fascicularis) as donors and baboons (Papio anubis) as recipients.

Chronic rejection of rat aortic allograft was studied by Mennander et al. (1991) . Administration of cyclosporine induced accelerated allograft arteriosclerosis.

Heterotopic transplantation of small intestine has been performed from BN to LEW rats. The mesenteric venous drainage is reconstructed either via the vena cava or the portal vein ). An isolated Thiry-Vella loop was prepared by Xia and Kirkman (1990) . Kellnar et al. (1990) described allogenic transplantation of fetal rat intestine with anastomosis to the normal bowel of the host. Langrehr et al. (1991) investigated under which circumstances graftversus-host disease occurs following fully allogenic small bowel transplantation in the rat. Kirsch et al. (1991) studied the extent to which intestinal transplants in rats undergo functional and morphologic compensation.

Liver transplantation procedure has been described by Svensson et al. (1995) , allowing measurement of bile secretion.

Orthotopic left lung transplantation was performed in inbred rats by Katayama et al. (1991) .

Tracheal allografts were implanted into the abdomen of recipient rats (Davreux et al. 1993) .

In vivo electrophysiology of rat peripheral nerve transplants was studied by Yu et al. (1990) . A sciatic-tibial nerve graft was harvested from the donor rat between the sciatic notch and the ankle. In the recipient, the tibial nerve and the sural nerve were resected. The nerve graft was placed along the natural course of the native tibial nerve. Nerve repair was performed using standard end-to-end epineural microsuture technique.

A model of neurovascularized rectus femoris muscle transplantation in rats was established by Muramatsu et al. (1994) .

The orthotopic transplantation of vascularized skeletal allografts (rat distal femur and surrounding muscular cuff) has been described by Lee et al. (1995) .

Long-term survival of limb allografts in rats was studied by Kuroki et al. (1991) . The donor and recipient limbs were prepared simultaneously by amputation at mid-femur. The donor limb was fixed orthotopically by Kirschner wire. The donor and recipient femoral arteries, veins, and sciatic nerves were anastomosed using a microsurgical technique.

For cornea transplantation, Brown Norway rats (RT1 1Ân ) serve as donors and Lewis rats (RT1 1 ) as recipients ). Both the donor and recipient rats are anesthetized with xylazine hydrochloride and ketamine hydrochloride. Twenty min prior to surgery, the recipient rats also receive 0.5 mg/kg atropine sc. and phenylephrine hydrochloride 5 % eyedrops. Under sterile conditions and using an operation microscope, two donor corneal buttons (3.5 mm) are harvested from the donor rat using a trephine and curved Castroviejo scissors. The donor animals are then sacrificed by ether inhalation. The left eyes of the recipient rats are prepared by removing a central 3.0-mm button using a trephine and curved Castroviejo scissors. A drop of sterile methylcellulose (1 %) is placed over the 3.0-mm corneal opening before the donor cornea is fixed with 10 interrupted sutures. The anterior chamber is not reestablished following surgery. Prior to closure of the eyelids with three or four interrupted sutures, Polyspectran eyelid gel is placed over the operated eye. Forty-eight hours following surgery, the eyelid sutures are removed, allowing for the first time assessment of the cornea on the slit-lamp microscope. Slitlamp evaluations are performed every 2-3 days under i.m. anesthesia with ketamine, with assessment of the cornea by scoring graft opacity, edema, and vascularization.

Recently the role of indoleamine 2,3-dioxygenase as an immunomodulator has been reviewed in models of allogenic pancreatic islet and skin transplantation (Gill et al. 2013 Anti-Anaphylactic Activity 

Cyclosporin A induces long-term unresponsiveness in mercuric chloride-induced autoimmune glomerulonephritis

Effect of cyclosporin A on mercury-induced autoimmune glomerulonephritis in the Brown Norway rat

Effect of cyclosporin on active Heymann nephritis

Experimental crescentic glomerulonephritis: a new bicongenic rat model

Effect of the immunosuppressive agent, cyclosporin, on experimental immune complex glomerulonephritis in rats

Effect of cyclosporin A on autoimmune tubulointerstitial nephritis in the brown Norway rat

The effect of cyclosporin A on the interstitial mononuclear cell infiltration and the induction of Heymann's nephritis

Experimental graft arteriosclerosis

Rapamycin in a renal transplant model

Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection

Regulatory B cells and tolerance in transplantation: from animal models to human

Leflunomide therapy following penetrating keratoplasty in the rat

Cardiac transplantation in the rat

References and Further Reading Inhibition Of Histamine Release from Mast Cells 2nd edn

Mitogen-induced lymphocyte proliferation in logger head sea turtles: comparison of methods and effects of gender, plasma testosterone concentration and body condition on immunity

Mitogen-induced B-cell proliferation activates Chk2-dependent G1/S cell cycle arrest

Lymphocyte populations. Evaluation of T and B populations, T cell subpopulations and K cells

Standardisation of the mixed lymphocyte reaction

Modulation of B and T cell subsets in mice treated with fractionated total lymphoid irradiation. I. Blockade of differentiating B cell pathways

Leflunomide, a novel immunosuppressive agent

Leflunomide, a novel immunomodulatory agent: in vitro analyses of the mechanism of immunosuppression

Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506

Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism

Pharmacology of cyclosporine (Sandimmune) V. Pharmacological effects on immune function: in vitro studies

T lymphocyte-proliferative responses of a grey seal (Halichoerus grypus) exposed to heavy metals and PCBs in vitro

Alternatively activated macrophages inhibit T-cell proliferation by stat6-dependent expression of PD-L2

Impact of different cell isolation techniques on lymphocyte viability and function

Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon

PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing cdc-25A

Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection

Standardisation of the mixed lymphocyte reaction

Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers

The influence of leflunomide on cell cycle, IL-2-receptor (IL-2-R) and its gene expression

Rat mesenchymal stromal cells inhibit T cell proliferation but not cytokine production through inducible nitric oxide synthase

Immunopharmacological profile of HWA 486, a novel isoxazol derivative-II. in vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone, or cyclosporin A

An appraisal of the technique of polymorphonuclear leukocyte chemiluminescence as a means to detect compounds with antiinflammatory activity

Increased superoxide anion production by immunologically activated and chemically elicited macrophages

Inhibitory effects of azelastine on superoxide anion generation from activated inflammatory cells measured by a simple chemiluminescence method

Chemiluminescence response of human blood mononuclear cells to PAH and histamine

High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase

Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide

Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening

Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases

Babesia bovis dihydroorotate dehydrogenase (BboDHODH) is a novel molecular target of drug for bovine babeosis

Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives

Functional expression of a fragment of human dihydro-orotate dehydrogenase by means of the baculovirus vector system, and kinetic investigation of the purified enzyme

Rat dihydroorotate dehydrogenase: isolation of the recombinant enzyme from mitochondria of insect cells

Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents

Wirth DF Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans

De novo pyrimidine biosynthesis in Jurkat T cells is inhibited by leflunomide's primary metabolite A77-1726 at the level of dihydroorotate dehydrogenase

An update on the biology of sphingosine-1-phosphate receptors

Sphingosine kinase-1 mediates TNF-α induced MCP-1 gene expression in endothelial cells: upregulation by oscillatory flow

Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases

Phospholipase D activation by sphingosine 1-phosphate regulates interleukin-8 secretion in human bronchial epithelial cells

Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs

Sphingolipids as bioactive regulators of thrombin generation

Nitric oxide induces degradation of the neutral ceramidase in rat mesangial cells and is counterregulated by protein kinase C

Nitric oxide induces neutral ceramidase degradation by the ubiquitin/proteasome complex in renal mesangial cell cultures

Emerging medical roles for lysophospholipid signaling

Ceramide: an intracellular signal for apoptosis

Ceramide in apoptosisdoes it really matter?

Nitric oxide donors induce stress signaling via ceramide formation in rat renal mesangial cells

Nitric oxide stimulates ceramide formation in glomerular endothelial cells

Altering the sphingosine-1-phosphate/ceramide balance: a promising approach to tumor therapy

Sphingosine kinase signaling in immune cells

Lysophospholipids increase ICAM-1 expression in HUVEC through a G i -und NF-κB-dependent mechanism

Sphingosine kinase: a point of convergence in the action of diverse neutrophil priming agents

Signal transduction of stress via ceramide

Protective effects of sphingosine 1-phsophate in murine endotoxin-induced inflammatory lung injury

The balance between sphingosine and sphingosine-1-phosphate is decisive for mast cell activation after Fcε receptor I triggering

Sphingosine 1-phosphate signaling in mammalian cells

Sphingosine 1-phosphate pathway therapeutics: a lipid ligand-receptor paradigm

Sphingosine-1-phosphate and its receptors: structure, signaling, and influence

Sphingosine kinase: biochemical and cellular regulation and role in disease

The role of sphingosine-1-phosphate in smooth muscle contraction

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

Fingolimod for the treatment of neurological diseasesstate of play and future perspectives

FTY720, a new class of immunomodulators, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors

Fingolimod (FTY720), the sphingosine 1-phosphate receptor modulator, as a new therapeutic drug in multiple sclerosis

Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine 1-phosphate and FTY720: discovery of potent S1P 1 receptor agonists

) 2,5-Disubstituted pyrrolidines carboxylates as potent, orally active sphingosine-1-phosphate (S1P) receptor agonists

Sphingosine 1-phosphate analogs as receptor antagonists

Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate agonists in rodents are mediated via distinct receptor subtypes

Synthesis, stability, and implications of phosphothioate agonists of sphingosine-1-phosphate receptors

Fungal metabolites. Part II. A potent immunosuppressive activity found in Isaria sinclairii metabolite

A sphingosine-1-phosphate receptor-1 directed agonist reduces central nervous system inflammation in a plasmacytoid dendritic cell-dependent manner

The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate Gprotein-coupled receptors

Discovery, design and synthesis of a selective S1P3 receptor allosteric agonist

Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection

The discovery of 3-(N-alkyl) aminopropylphosphonic acids as potent S1P receptor agonists

Synthesis, stereochemical determination and biochemical characterization of the enantiomeric phosphate esters of the novel immunosuppressive agent FTY720

Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720

Characterization of a novel sphingosine 1-phosphate receptor, Edg-8

Characterization of the human and mouse sphingosine 1-phosphate receptor, S1P 5 (Edg-8): structure-activity relationship of sphingosine 1-phosphate receptors

Development of a selective S1P 1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis

S1P 1 -selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling and fate

Sphingosine kinasemediated Ca2+ signalling by G-protein-coupled receptors

Quantitative measurement of sphingosine 1-phosphate by radioreceptor-binding assay

Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P 1 )

Sphingosine 1-phosphate receptor agonists: a patent review

Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis

Sphingosine 1-phosphate (S1P) receptor subtypes S1P 1 and S1P 3 , respectively, regulate lymphocyte recirculation and heart rate

A sphingosine 1-phosphate receptor 2 selective allosteric agonist

Inhibition of Th1-and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720

The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4 + /CD25 + T-regulatory cells and enhances their functional activity

Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P 2 and S1P 3 receptors and Smadindependent signaling

FTY720/ fingolimod, a sphingosine analogue, reduces amyloidβ production in neurons

Heterologous desensitization of the sphingosine 1-phosphate receptors by purinoceptor activation in renal mesangial cells

The immunomodulators FTY720 and its phosphorylated derivative activate the Smad signaling cascade and upregulate connective tissue growth factor and collagen IV expression in renal mesangial cells

ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile

FTY720 for cancer therapy (review)

Distinctive G protein-dependent signaling in smooth muscle by sphingosine 1-phosphate receptors S1P 1 and S1P 2

FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase

Systemic application of sphingosine 1-phosphate receptor 1 immunomodulator inhibits corneal allograft rejection in mice

Basal and induced sphingosine kinase 1 activity in A549 carcinoma cells: function in cell survival and IL-1 β and TNF-α induced production of inflammatory mediators

Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease

Endothelial nitric oxide synthase activation by tumor necrosis factor a through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 receptors

The epidermal growth factor stimulates sphingokinase-1 expression and activity in the human mammary carcinoma cell line MCF7

Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration

Role of sphingosine kinase 2 in cell migration toward epidermal growth factor

Histamine increases sphingosine kinase-1 expression and activity in the human endothelial cell line E.A.hy926 by a PCK-α-dependent mechanism

Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis

Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720

Molecular cloning and functional characterization of murine sphingosine kinase

Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond

Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform

Sphingosine kinase 2 is a putative BH3-only protein that induces apoptosis

Functional characterization of human sphingosine kinase-1

Roles, regulation and inhibitors of sphingosine kinase 2

Involvement of N-terminalextended form of sphingosine kinase 2 in serumdependent regulation of cell proliferation and apoptosis

Assaying sphingosinekinase activity

The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2

Importance of sphingosine kinase (SphK) as a target in developing cancer

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing

Role of sphingosine 1-phosphate (S1P) and effects of fingolimod, an S1P receptor 1 antagonist in lymphatic circulation and autoimmune disease

Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate agonists in rodents are mediated via distinct receptor subtypes

Activation of human monocytic cells by lysophosphatidic acid and sphingosine-1-phosphate

Role of sphingosine kinase 2 in cell migration toward epidermal growth factor

CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720

Histamine increases sphingosine kinase-1 expression and activity in the human endothelial cell line E.A.hy926 by a PCK-α-dependent mechanism

Inhibition of chemotactic motility and trans-endothelial migration of human neutrophils by sphingosine 1-phosphate

Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720

The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34 + progenitor cells

Sphingosine 1-phosphate regulates peritoneal B-cell trafficking for subsequent intestinal IgA production

Alteration of lymphocyte trafficking by sphingosine receptor agonists

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate

Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines the lymphocyte egress kinetics

FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo

FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats

Blocking lymphocyte trafficking with FTY720 prevents inflammation-sensitized hypoxic-ischemic brain injury in newborns

Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720

Characterisation of a novel and spontaneous mouse model of inflammatory arthritis

Thyroglobulin-reactive T lymphocytes in thyroiditis-prone BB/Wor rats

Decline in suppressor T cell function with age in female NZB mice

Spontaneous anemia in mice of the NZB/BL strain

Thymic function in NZB mice

Effects of cytokine application on glucocorticoid secretion in an animal model for systemic scleroderma

Preferential TCR Vβ1 gene usage by autoreactive T cells in spontaneous autoimmune thyroiditis of the obese strain of chickens

Hereditary hypothyroidism in domestic fowl

Hereditary autoimmune thyroiditis in the fowl

Inherited autoimmune thyroiditis in the fowl

Thyroiditis as a model of organ specific autoimmune disease

Development of spontaneous autoimmune thyroiditis in Obese strain (OS) chickens

The juvenile diabetes foundation workshop on the spontaneously diabetic BB rat: its potential for insight into human juvenile diabetes

Characterization of a spontaneous disease of white leghorn chickens resembling progressive systemic sclerosis (scleroderma)

Animal models of spontaneous autoimmune disease: type 1 diabetes in the non-obese diabetic mouse

Motheaten, an immunodeficient mutant of the mouse. I. Genetics and pathology

Analysis of the initiation period of spontaneous autoimmune thyroiditis (SAT) in the obese strain (OS) of chickens

Spontaneous development of autoimmune sialadenitis in aging BDF1 mice

Renal disease associated with positive lupus erythematosus test in a cross-bred strain of mice

Otic capsule bony lesions in the Palmerston North autoimmune mouse

Genetic, hormonal and behavioural influence on spontaneously developing arthritis in normal mice

The immunology and pathology of NZB mice

Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice

A laboratory model for Sjögren's syndrome

Immunogenetic analysis of spontaneous autoimmune thyroiditis of obese strain of chickens

Animal model of human disease. The non-obese diabetic (NOD) mouse

Spontaneous autoimmune diabetes mellitus in the BB rat

Breeding of a non-obese, diabetic strain of mice

The non-obese diabetic (NOD) mouse: an animal model for autoimmune thyroiditis

Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: a longitudinal study

Genetic background of spontaneous autoimmune thyroiditis in the obese strain of chickens studied in hybrids with an inbred line

Development of a spontaneous liver disease resembling autoimmune hepatitis in mice lacking tyro3, axl and mer receptor tyrosine kinases

Aspartate at position 57 of nonobese diabetic I-A (g7) β-chain diminishes the spontaneous incidence of insulin-dependent diabetes mellitus

A murine model of spontaneous aspermatogenesis: linkage to H 2

Autoimmune thyroiditis -spontaneous disease models -cat

Spontaneous autoimmune models

Pleiotropic effects of deleterious alleles in the "motheaten

Viable motheaten," a new allele in the motheaten locus

Animal model of human disease: autoimmune thyroiditis. Spontaneous autoimmune thyroiditis in praomys (mastomys) coucha

A substrain of NZB mouse as an animal model of autoimmune inner ear disease

Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor

Immunohistochemical analysis of otic capsule osteogenesis in the Palmerston North autoimmune mouse

Autoimmune disease of exocrine organs in immunodeficient alymphoplasia mice: a spontaneous model for Sjøgren's syndrome

Serial observations and definition of mononuclear cell infiltrates in avian scleroderma, an inherited fibrotic disease of chickens

Endocrine disturbance in obese chickens

The obese strain (OS) of chickens: an animal model with spontaneous autoimmune thyroiditis

Altered immunity and diabetes in the BB rat

A new model of spontaneous autoimmune peripheral polyneuropathy: implications for Guillain-Barre syndrome

Acute Systemic Anaphylaxis in Rats Austen KF, Brocklehurst WE (1961) Anaphylaxis in chopped guinea pig lung

An improved method for the perfusion of isolated lung of guinea pig

Studies with two new phosphodiesterase inhibitors (ICI 58,301 and ICI

Passive cutaneous anaphylaxis in the rat, induced with two homologous reaginlike antibodies and its specific inhibition with disodium cromoglycate

Actions of bradykinin antagonists on bradykinin-induced plasma extravasation, venoconstriction, prostaglandin E 2 release, nociceptor stimulation and contraction of the iris sphincter muscle of the rabbit

Resveratrol inhibits IgE-mediated basophilic mast cell degranulation and passive cutaneous anaphylaxis in mice

An immunoglobulin-like receptor, allergin-1, inhibits immunoglobulin E-mediated immediate hypersensitivity reactions

A new simple method for extraction of extravasated dye in the skin

New, long-acting, potent bradykinin antagonists

Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea pigs

The use of IgE mediated responses as a pharmacologic test system. The effect of disodium cromoglycate in respiratory and cutaneous reactions and in the electrocardiograms of rhesus monkeys

Vascular protein leakage in various tissues induced by substance P, capsaicin, bradykinin, histamine and by antigen challenge

Antigen and antibody detection by in vivo methods: a reevaluation of passive cutaneous anaphylactic reactions

Participation of proteinaseactivated receptor-2 in passive cutaneous anaphylaxisinduced scratching behaviour and the inhibitory effect of tacrolimus

Substituted 3-phenyl-7H-thiazolo (3,2-b)(1,2,4) triazin-7-ones as antiinflammatory agents with immunomodulating properties

Suppression of Arthus and delayed hypersensitivity reactions to bovine serum albumin by dopaminergic antagonists

Inhibitory effect of epinastine on the type II-IV allergic reactions in mice, rats and guinea pigs

Immunopharmacological studies of 4-acetylaminophenyl-acetic acid. (MS-932)

Acute effects of deflazacort and its metabolite 21-desacetyl-deflazacort on allergic reactions

Delayed Type Hypersensitivity (DTH)

Establishment and characterization of a sustained delayed-type hypersensitivity model with arthritic manifestations in C57/BL6J mice

Pharmacology of cyclosporine (Sandimmune). IV. Pharmacological properties in vivo

Effects of the new anti-lymphocytic peptide cyclosporin A in animals

Inhibition of delayed-type sensitivity by cucurbitacin R through the curbing of lymphocyte proliferation and cytokine expression by means of nuclear factor AT translocation to the nucleus

Induction of delayed-type hypersensitivity and interferon-gamma to Candida albicans and anti-henegg white lysozyme antibody as phenotypic markers of enhance bovine immune response

Mast cell degranulation as a major event in the effector phase of delayed-type hypersensitivity induced by cloned helper cells

Inhibitory effect of epinastine on the type II-IV allergic reactions in mice, rats and guinea pigs

Delayedtype hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy

Cutaneous delayed-type hypersensitivity in patients with atopic dermatitis

Antiinflammatory and immunosuppressive effects of 1,6-anhydro-3,4-dideoxy-2-furfuryl-β-Dthreo-3-enopyranose (MT 2221), a novel anhydroenopyranose derivative, on experimental animal models

Immunopharmacological studies of 4-acetylaminophenyl-acetic acid. (MS-932)

Relationship between systemic inflammation and delayed-type hypersensitivity response to Candida antigen in older adults

High incidence of heparininduced allergic delayed-type hypersensitivity reactions in pregnancy

A simple and effective method to assess murine delayed type hypersensitivity to proteins

Three protein cocktails mediate delayed-type hypersensitivity responses indistinguishable from that elicited by purified protein derivative in the guinea pig model of Mycobacterium tuberculosis infection

Immune complexes and inflammation. A study of the activity of anti-inflammatory drugs in the reverse passive Arthus reaction in the rat

Comparison of several new 5-lipoxygenase inhibitors in a rat Arthus pleurisy model

Phospholipase A 2 acyl-hydrolytic activity in rat RPARinduced pleurisy

NPC 15669 inhibits the reverse passive Arthus reaction in rats by blocking neutrophil recruitment

Antiinflammatory peptides (antiflammins) inhibit synthesis of platelet-activating factor, neutrophil aggregation and chemotaxis, and intradermal inflammatory reactions

) 5-Lipoxygenase inhibitory activity of Zileuton

Effects of pharmacologic agents on the reversed passive Arthus reaction in the rat

The mechanism of Arthus reactions. I. The role of polymorphonuclear leukocytes and other factors in reversed passive Arthus reactions in rabbits

The mechanism of Arthus reactions. II. The role of polymorphonuclear leukocytes and platelets in reversed passive Arthus reactions in the guinea-pig

Inhibitors of immune complex-induced inflammation: 5-substituted 3

Suppression of the Arthus reaction by Y-24180, a potent and specific antagonist of platelet-activating factor

Substituted 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-ones as potential antiinflammatory agents

A model for the quantitative study of Arthus (immunologic) hypersensitivity in rats

Adjuvant Arthritis in Rats

Erysipelothrix rhusiopathiae and spontaneous arthritis in pigs

Interleukin-1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not in polycation induced arthritis in the rabbit

Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model

Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis of the rat

Drug sensitivity of rat adjuvant arthritis, induced with 'adjuvants' containing no mineral oil components

Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis

Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis

Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis

Osteoclast numbers in Lewis rats with adjuvantinduced arthritis: identification of preferred sites and parameters for rapid quantitative analysis

Anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis

Antigeninduced arthritis in mice

Effect of calprotectin in avridine-induced arthritis

Increase in "pain sensitivity" induced by exercise applied during the onset of arthritis in a model of monoarthritis in the rat

Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis

Streptococcal arthritis and cardiomyopathy experimentally induced in white mice

Experimental arthritis in rabbits produced by streptococci and other organisms

Evidence that adjuvant arthritis in the rat is associated with chronic pain

Alteration of interleukin-1 production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin-A or methotrexate

Production of a chronic arthritis with albumin. Its retention in rabbit knee joints

Arthritis produced by intraarticular injection of streptolysin S in rabbits

The pathogenesis of chronic inflammation in experimental antigen-induced arthritis. I. The role of antigen on the local immune response

The pathogenesis of chronic inflammation in experimental antigen-induced arthritis. II. Preferential localization of antigen-antibody complexes to collagenous tissues

Monarticular antigen-induced arthritis in rabbits and mice

The role of bradykinin B 1 receptors in the maintenance of intra-articular plasma extravasation in chronic antigen-induced arthritis

Mycoplasma infection and arthritis in chickens

The cyclopentenone prostaglandin 15-deoxy-Δ 12,14 -prostaglandin J 2 attenuates the development of acute and chronic inflammation

Targeting TNF-a and NF-kB activation by bee venom: role in suppressing adjuvant induced arthritis and methotrexate hepatotoxicity in rat

Measurement of radiographic changes in adjuvant-induced arthritis in rats by quantitative image analysis

Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis

Highly-water soluble matrix metalloproteineases inhibitors and their effects in a rat adjuvant-induced arthritis model

The experimental production of arthritis. A review

A robust model of adjuvant-induced chronic unilateral arthritis in two mouse strains

Experimental arthritis in rabbits induced by group A streptococcal products

Experimental models of streptococcal arthritis: pathogenic role of streptococcal products and prostaglandins and their modification by anti-inflammatory agents

Experimental models of chronic inflammatory diseases

Metalloproteinases and cartilage proteoglycan depletion in chronic arthritis. Comparison of antigen-induced and polycation-induced arthritis

An epizootic in Swiss mice caused by a group A streptococcus, newly designed type 50

The role of tumor necrosis factor-alpha and IL-1 in polymorphonuclear leukocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis

Persistence of antigen in experimental allergic monoarthritis

Experimental arthritis in rats. A comprehensive review with specific reference to mycoplasma

Animal models of rheumatoid arthritis

15-deoxy-Δ 12,14 -PGJ 2 induces synoviocyte apoptosis and suppresses adjuvantinduced arthritis in rats

Evaluation of analgesic agents in rats with adjuvant arthritis

Pathology of chickens inoculated experimentally or contact-infected with Mycoplasma synoviae

Inflammatory polyarthritis by mercuric chloride in the Brown Norway rat

Anti-CD8 treatment reduces the severity of inflammatory arthritis, but not vasculitis, in mercuric chloride-induced autoimmunity

The determinants of susceptibility/resistance to adjuvant arthritis in rats

Polyarthritis induced in the rat by cell walls from several bacteria and two Streptomyces species

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

Interleukin-6 serum levels correlate with footpad swelling in adjuvant-induced arthritic Lewis rats treated with cyclosporin A or indomethacin

Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo

Antifibrotic action of interleukin-1 receptor antagonist in lapine monoarticular arthritis

Comparative susceptibility of DA, LEW, and LEW.1AV1 rats to arthritis induced by different arthritogens: mineral oil, mycobacteria, muramyl dipeptide avridine and rat collagen II

Arthritis in Lewis rats induced by the non-immunogenic adjuvant CP20961: an immunohistochemical analysis of the developing disease

Adjuvant arthritis

Animal models of rheumatoid arthritis

Experimental rheumatoid arthritis in rabbits

Relation to rheumatic-like lesions of the mouse to localization of group A streptococci cell walls

Enlarged joint condition in poultry caused by an infectious agent

Control of infectious synovitis. The antigen study of three strains

Development of arthritis, periarthritis and periostitis in rats given adjuvants

Experimental joint disease. Observations on adjuvant-induced arthritis

Studies on polyarthritis and other lesions induced in rats by injection of mycobacterium adjuvant. I. General clinic and pathological characteristics and some modifying factors

The use of a standardized adjuvant arthritis assay to differentiate between anti-inflammatory and immunosuppressive agents

A new method for the evaluation of analgesic activity using adjuvant-induced arthritis in the rat

Pathologic changes of porcine suppurative arthritis produced by Streptococcus equisimilis

Electron microscopy of porcine synovial membrane cell layer in Streptococcus equisimilis arthritis

The analgesic and antiinflammatory profile of (AE À 5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2a]pyrrole-1-carboxylic acid (RS-37619)

Preclinical studies with 15-deoxyspergualin in various animal models for autoimmune diseases

Disease-modifying activity of malononinitrilamides, derivates of leflunomide's active metabolite, on models of rheumatoid arthritis

Experimenteller Rotlauf bei verschiedenen Spezies als Ursache einer systemischen Bindegewebskrankheit. I. Systemische vaskuläre Prozesse bei der Organmanifestation

Experimenteller Rotlauf bei verschiedenen Spezies als Modell einer systemischen Bindegewebskrankheit. II. Chronische Phase mit besonderer Ber€ ucksichtigung der Polyarthritis

Hemostasis, fibrin incorporation and local mesenchymal reaction in erysipelothrix infection as a model for rheumatism research

Inhibition of adjuvant-induced arthritis by nasal administration of novel synthetic peptides from heat shock protein 65

Studies on the etiology of rheumatic arthritis. III. Experimental production of arthritis in rabbits following focal infection of paranasal sinus with hemolytic streptococcus

Evaluation of complete Freund's adjuvantinduced arthritis in a Wistar rat model

Chronic self-perpetuating arthritis induced in rabbits by a cell-free extract of group A streptococci

Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro-10-oxodibenzo[b, f]thiepin-2-yl) propionic acid. 4th communication: inhibitory effects on rat adjuvant arthritis

Matrix metalloproteinases as targets for the immune system during experimental arthritis

Avridineinduced arthritis in rats: a T cell-dependent chronic disease influenced both by MHC genes and by non-MHC genes

In vivo therapy monitoring of experimental rheumatoid arthritis in rats using nearinfrared fluorescence imaging

Effects and mechanisms of FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor, on adjuvant arthritis in rats

Adjuvant-induced arthritis in rats -temporal relationship of drug effects on physiological, biochemical, and haematological parameters

Anti-arthritic effect of astragaloside IV and its molecular mechanism

Rat adjuvant arthritis: a model of chronic inflammation

Production of synovitis in rabbits by fractions of a cell-free extract of Erysipelothrix rhusiopathiae

Strain and sex variation in the susceptibility to streptococcal wall-induced polyarthritis in the rat

Thymus-dependent and -independent regulation of Ia antigen expression in situ by cells in the synovium of rats with streptococcal cell wall-induced arthritis

Inhibition by cyclosporin A of streptococcal wall-induced arthritis and hepatic granulomas in rats

Ciclamilast ameliorates adjuvant-induced arthritis in a rat model

Wesa AK Visualizing arthritic inflammation and therapeutic response by fluorine-19 magnetic resonance imaging ( 19 F MRI)

Visualizing arthritic inflammation and therapeutic response by fluorine-19 magnetic resonance imaging (19F MRI)

Evaluation of therapeutic targets in animal models arthritis

Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy

Effects of indomethacin, cyclosporin, cyclophosphamide, and placebo on collageninduced arthritis of mice

Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases

Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs

Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor γ

Amelioration of collagen-induced arthritis by a novel SIP 1 antagonist with immunomodulatory activities

Utility of animal models for identification of potential therapeutics for rheumatoid arthritis

The anti-arthritic and immunosuppressive effects of cyclosporine on arthritis induced in the rat by type II collagen

The progression of the inflammation in established collagen-induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities

Attenuation of collagen-induced arthritis in rat by nicotinic alpha7 receptor partial agonist GTS-21

Inhibition of cartilage degradation in rat collagen-induced arthritis but not adjuvant arthritis by the neutrophil elastase inhibitor MDL 101,146

Accelerated onset of collagen-induced arthritis by remote inflammation

IL-1αβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation

Paradoxical effects of cyclosporin A on collagen arthritis in rats

Regulatory T cells specific for the same framework 3 region of the Vβ8.2 chain are involved in the control of collagen II-induced arthritis and experimental autoimmune encephalomyelitis

Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938

Neurostimulation of the cholinergic antiinflammatory pathway ameliorates disease in rat collagen-induced arthritis

Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy

Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion

A highly selective inhibitor of IκB kinase, BMS-.345541, blocks both inflammation and destruction in collagen-induced arthritis in mice

Reactivity of an active center analog of Cu 2 Zn 2 -superoxide dismutase in murine model of acute and chronic inflammation

Suppression of arthritis by an active center analogue of Cu 2 Zn 2 -superoxide dismutase

Arthritogenic reactivity of chromium (V)

Antigen-specific T cell sensitization in impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses

Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice

Successful treatment with a novel immunosuppressive agent, deoxyspergualin, in type II collagen-induced arthritis in mice

Effects of various anti-inflammatory drugs on type II collagen-induced arthritis in rats

Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis

-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigeninduced T cell proliferation

Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis

Animal models of rheumatoid arthritis: correlation and usefulness with human rheumatoid arthritis

Soluble IL-15 receptor α-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology

Effects of anti-arthritic compounds on type II collagen-induced arthritis in rats

Development and optimization of a high throughput micro-computed tomography imaging method incorporating a novel analysis technique to evaluate bone mineral density of arthritic joints in a rodent model of collagen induced arthritis

Effects of cyclosporin on collagen induced arthritis in mice

Comparative study of effects of cyclosporins A and G on collagen arthritis in mice

Pharmacological studies of the new anti-inflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. 1st communication: anti-inflammatory, analgesic and other related properties

Type II collagen-induced arthritis in the rat

Autoimmunity to type II collagen: an experimental model of arthritis

The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice

Autologous stem cell transplantation in experimental arthritis by renewal and modulation of the Teff cell compartment

Proteoglycan-induced arthritis in BALB/c mice: clinical features and histopathology

Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide

Proteoglycan (PG)-induced arthritis (PGIA) and recombinant human PG-G1 domain-induced arthritis (GIA) in BALB/c mice resembling two subtypes of rheumatoid arthritis

Aggregation of proteoglycans. I. The role of hyaluronic acid

Extraction, fractionation and characterization of proteoglycans from bovine tracheal cartilage

Immunity to cartilage proteoglycans in BALB/c mice with progressive polyarthritis and ankylosing spondylitis induced by injection of human cartilage proteoglycan

Proteoglycan-induced polyarthritis and spondylitis adoptively transferred to naive

Cartilage proteoglycan-induced arthritis: a combined model for rheumatoid arthritis and ankylosing spondylitis

Chronic remittent erosive arthritis induced by bacterial peptidoglycanpolysaccharide structures

Mesenchymal stem cell therapy in proteoglycan induced arthritis

Pristane-Induced Arthritis in Mice

Effects of cytogenin on spontaneous arthritis in MRL/1 mice and on pristane-induced arthritis (PIA) in DBA/1J mice

The immunological involvement in the pathogenesis of pristaneinduced arthritis

The non-MHC quantitative trait locus Cia5 contains three major arthritis genes that differentially regulate disease severity, pannus formation, and joint damage in collagen-and pristane-induced arthritis

Thermal signature analysis as a novel method for evaluating inflammatory arthritis activity

Endotoxin induces late increase un the production of pulmonary proinflammatory cytokines in murine lupus-like pristane-primed models

Pristaneinduced arthritis. II. Genetic regulation in F1 hybrid mice and cellular abnormalities following pristane injection

Pristane-induced arthritis loci interact with the Slc11a1 gene to determine susceptibility in mice selected for high inflammation

Comparison between the protective effects of mycobacterial 65-kD heat shock protein and ovomucoid in pristaneinduced arthritis. relationship with agalactosyl IgG

Pristane, a non-antigenic adjuvant induces MHC class II-restricted, arthritogenic T cells in the rat

Pristaneinduced arthritis in BALB/c mice. I. Clinical and histological features of the arthropathy

Involvement of antibody trait loci in the susceptibility to pristane-induced arthritis in the mouse

Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis

Pristane induced arthritis in mice. IV. Immunotherapy with mononuclear antibodies directed against lymphocyte subsets

Susceptibility of mast cell-deficient W/Wv mice to pristane-induced experimental lupus nephritis

Both common and unique susceptibility genes in different rat strains with pristaneinduced arthritis

Immune reactivity to connective tissue antigens in pristaneinduced arthritis

Protective effects of D-penicillamine and a thiazole derivative, SM-8849, on pristane-induced arthritis in mice

Identification and isolation of dominant susceptibility loci for pristane-induced arthritis

Characterization of pristine-induced arthritis, a murine model of chronic disease. Response to antirheumatic agents, expression of joint cytokines, and immunopathology

Genetics of susceptibility of pristine-induced plasmacytomas in BALB/sAn: reduced susceptibility in BALB/cJ with a brief description of pristine-induced arthritis

Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus

Antinuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane

Pristane-induced arthritis is CD4 + T cell dependent

Autoimmune reactions to heat-shock proteins in pristane-induced arthritis

An immunodominant epitope from mycobacterial 65-kDa heat shock protein protects against pristane-induced arthritis

Pristane-induced arthritis in mice selected for maximal or minimal acute inflammatory reaction

Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by major histocompatibility complex and non-major histocompatibility complex genes

Chronicity of pristane-induced arthritis in rats is controlled by genes on chromosome 14

Pristane-induced arthritis in mice. III Lymphocyte phenotypic and functional abnormalities precede the development of pristineinduced arthritis

Pristane-induced arthritis: the immunological and genetic features of an experimental murine model of autoimmune disease

Pristaneinduced arthritis in mice. V. Susceptibility to pristine-induced arthritis is determined by the genetic regulation of the T cell repertoire

Complete Freund's adjuvant suppresses the development and progression of pristaneinduced arthritis in rats

Complete Freund's adjuvant promotes the increase of IFN-γ and nitric oxide in suppressing chronic arthritis induced by pristane

Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis

Arthritis in rats after systemic injection of streptococcal cells or cell walls

Different roles of tumor necrosis factor α and interleukin 1 in murine streptococcal cell wall arthritis

Effects of the phosphodiesterase inhibitor rolipram on streptococcal cell wall-induced arthritis in rats

Targeting the P2X 7 receptor in rheumatoid arthritis: biological rationale for P2X 7 antagonism

Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate

Gene expression profiles in the rat streptococcal cell wall-induced arthritis model identified using microarray analysis

Streptococcal cell wallinduced arthritis: requirements for IL-4, IL-10, IFN-γ and monocyte chemoattractant protein-1

Role of chemokines and cytokines in a reactivation model of arthritis induced by injection with streptococcal cell walls

Streptococcal cell wall-induced arthritis and flare-up reaction in mice induced by homologous or heterologous cell walls

Immunomodulation of streptococcal cell wall-induced arthritis. Identification of inflammatory cells and regulatory T cell subsets by mercuric chloride and in vivo CD8 depletion

Disease modifying effects of N-butyryl glucosamine in a streptococcal cell wall induced arthritis model in rats

Inhibition by cyclosporin A of streptococcal cell wall-induced arthritis and hepatic granulomas in rats

Recombinant thyrotropin receptor and the induction of autoimmune thyroid disease in BALB/c mice: a new animal model

Transfer of thyroiditis, with syngeneic spleen cells sensitized with the human thyrotropin receptor, to naive BALB/c and NOD mice

Modulation of apoptosis: new opportunities for drug discovery to treat autoimmune thyroiditis

In vivo beneficial effects of cyclosporin A and 1,25-dihydroxyvitamin D 3 on the induction of experimental autoimmune thyroiditis

Characterization of autoimmune thyroiditis in MRL-lpr/lpr mice

Reduced cell-cell communication in experimentally induced autoimmune thyroid disease

The influence of cyclosporin A on the induction of experimental autoimmune thyroid disease in the PVG/c rat

Autoimmune thyroid disorders

The influence of cyclosporin A on experimental autoimmune thyroid disease in the rat

Iodine excess as an environmental risk factor for autoimmune thyroid disease

Experimental autoimmune thyroiditis in human parvovirus B10 transgenic mice

Thyroiditis in T cell-depleted rats: influence of strain, radiation dose, adjuvants and antilymphocyte serum

Experimental autoimmune thyroiditis induced by a 5-10 kDa tryptic fragment from porcine thyroglobulin

Inhibitory effect of FK 506 on autoimmune thyroid disease in the PVG rat

Effect of cyclosporine on experimental autoimmune thyroiditis in mice

Autoimmune murine thyroiditis relation to histocompatibility (H-2) type

Overexpression of BID in thyroids of transgenic mice increases sensitivity to iodine-induce autoimmune thyroiditis

Coxsackievirus B3-Induced Myocarditis

Identification of a putative shared epitope between Coxsackie virus B4 and alpha cardiac myosin heavy chain

Mucosal co-immunisation with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis

Autoimmunity is L3T4 + T helper cell and IL-2 independent in Balb/c mice

Coxsackie virus B-3 myocarditis. T-cell autoimmunity to heart antigens is resistant to cyclosporin-A treatment

Immunosuppressives in murine myocarditis

Complement receptor 1 and 2 deficiency increases Coxsackievirus B3-induced myocarditis, dilated cardiomyopathy and heart failure by increasing macrophages, IL-1b, and immune complex deposition in the heart

Epitopes shared between Coxsackievirus B3 (CVB3) and normal heart tissue contribute to CVB3-induced murine myocarditis

MiR-21 confers resistance against CVB3-induced myocarditis by inhibiting PDCD4-mediated apoptosis

Coxsackie virus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens

Coxsackie virus B-3 myocarditis. Identification of different pathogenic mechanisms in DBA/2 and Balb/c mice

LPS promotes CB3-induced myocarditis in B10. A mice

Galectin-9 administration ameliorates CVB3 induced myocarditis by promoting the proliferation of regulatory T cells and alternatively activated Th2 cells

Therapy with cyclosporine in experimental murine myocarditis with encephalomyocarditis virus

The effects of cyclosporine on acute murine Coxsackie B-3 myocarditis

The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male mice

Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis

Autoimmunity in myocarditis: models and mechanisms

Blockade of interleukin-17A protects against Coxsackievirus B3-induced myocarditis by increasing COX-2/PGE2 production in the heart

Oral administration of interferon-a-2b-transformed Bifidobacterium longum protects BALB/c mice against Coxsackievirus B3-induced myocarditis

Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection

Gene therapy with CCL2 (MCP-1) mutant protects CVB3-induced myocarditis by compromising Th1 polarization

Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle

Comparison of effects of Ivabradine versus Carvedilol in murine model with the Coxsackie virus B3-induced viral myocarditis

Myocarditis, disseminated infection, and early viral persistence following experimental coxsackievirus B infection of cynomolgus monkeys

Beneficial effects of leflunomide on cardiac myosin-induced experimental autoimmune myocarditis in rats

Attenuation of experimental autoimmune myocarditis by si-RNA mediated CD40 silencing

Erythromycin treatment suppresses myocardial injury in autoimmune myocarditis in rats via suppression of superoxide production

Mononuclear cell secretome protects from experimental autoimmune myocarditis

Localization of porcine cardiac myosin epitopes that induce experimental autoimmune myocarditis

Effects of 15-deoxyspergualin on experimental autoimmune giant cell myocarditis of the rat

Experimental rat model representing both acute and chronic failure related to autoimmune myocarditis

Fusidin ameliorates experimental autoimmune myocarditis in rats by inhibiting TNF-α production

Cardiac myosin from pig heart ventricle: purification and enzymatic properties

Autoimmune myocarditis, valvulitis and cardiomyopathy

Experimentally induced autoimmune myocarditis: production of heart myosin-specific antibodies

Cardiac myosin-induced myocarditis. Heart autoantibodies are not involved in the induction of the disease

Cardiac myosin-induced myocarditis as a model of postinfectious autoimmunity

Alternatively activated M2 macrophages increase in early stages of experimental autoimmune myocarditis in Lewis rats

The Ras antagonist farnesylthiosalicylic acid ameliorates experimental myocarditis in the rat

Induction of experimental autoimmune myocarditis in mice lacking CD3 or CD8 molecules

Cellular infiltrate, major histocompatibility antigen expression and immunopathogenic mechanisms in cardiac myosin-induced myocarditis

Cardioprotective effects of Telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/Mas receptor axis

A specific inhibitor of plasminogen activator inhibitor-1 suppresses rat autoimmune myocarditis

A histological study on experimental autoimmune myocarditis with special reference to initiation of the disease and cardiac dendritic cells

Idiopathic giant cell myocarditis: state of the art

Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy

Experimental allergic encephalomyelitis: a useful model for multiple sclerosis

Experimental allergic encephalomyelitissusceptibility and suppression

Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice

Cytokines in the nervous system of mice during chronic relapsing experimental allergic encephalomyelitis

Cannabinoids control spasticity and tremor in a multiple sclerosis model

Experimental autoimmune encephalomyelitis (EAE) mediated by T cell lines: process of selection of lines and characterization of the cells

Immunosuppression by cyclosporin A of experimental allergic encephalomyelitis

Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases

Rapamycin, a potential disease-modifying antiarthritic drug

SRI 62-834, a cyclic ether analogue of the phospholipid ET-18-OCH 3 , displays long-lasting beneficial effects in chronic relapsing encephalomyelitis in the Lewis rat. Comparison with cyclosporin and (Val 2 )-dihydrocyclosporin effects in clinical, functional and histological studies

Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis

Mouse model for multiple sclerosis: historical facts and future implications

Evaluation of the role of erythropoietin and methotrexate in multiple sclerosis

Expression of the tyrosine phosphatase Src homology 2 domaincontaining protein tyrosine phosphatase 1 determines T cell activation threshold and severity of experimental autoimmune encephalomyelitis

The relevance of animal models in multiple sclerosis research

Ligands for the peroxisome proliferator-activated receptor-γ and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis

Longitudinal in vivo magnetic resonance imaging studies in experimental allergic encephalomyelitis : effect of a neurotropic treatment on cortical lesion development

Preventive and therapeutic effects of cyclosporin and valine 2 -dihydrocyclosporin in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat

A polyalanine peptide with only five native basic protein residues induces autoimmune encephalomyelitis

Creation of a model for multiple sclerosis in Callithrix jacchus marmosets

Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis

Synchronous synthesis of α-and βchemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis

Cyclosporin A prevents P2 T cell line-mediated experimental autoimmune neuritis (AT-EAN) in rat

Chronic relapsing experimental autoimmune encephalomyelitis in mice: enhancement by monoclonal antibodies against interferon-gamma

The influence of cyclosporin A on the development of actively induced and passively transferred experimental allergic encephalomyelitis

Suppression of experimental allergic neuritis by cyclosporin A

Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 β molecule, a calcium binding protein of astroglia

Suppression of the hyperacute form of experimental allergic encephalomyelitis by drugs

Experimental autoimmune encephalomyelitis in IL-4 deficient mice

Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines

Protective effect of the interleukin-1 antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats

Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: a new model of multiple sclerosis

CNS gene expression pattern associated with spontaneous experimental autoimmune encephalomyelitis

The effects of prophylactic cyclosporin A on experimental allergic neuritis (EAN) in the Lewis rat. Induction of relapsing EAN using low dose of cyclosporin A

Experimental allergic encephalomyelitis in the rat: response to encephalitogenic proteins and peptides

Effect of stilbene-type anion channel blockers on the immune response during experimental allergic neuritis

Cinnamon ameliorate experimental allergic encephalomyelitis in mice via regulatory T cells: implications for multiple sclerosis therapy

Suppression of actively induced and passively transferred experimental allergic neuritis by cyclosporin A

Experimental models of multiple sclerosis

Amelioration of experimental autoimmune encephalomyelitis by anatabine

Induction of a heterogeneous TCR repertoire in (PL/JXSJL/J) F2 mice by myelin basic protein peptide Ac1-11 and its analog Ac1-11

The EAE-associated behavioral syndrome: II. Modulation by anti-inflammatory treatments

Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat

The role of CTLA-4 in tolerance induction and T cell differentiation in experimental autoimmune encephalomyelitis.: i.p. antigen administration

Observations on attempts to produce acute disseminated encephalomyelitis in monkeys

Chemotherapy of experimental allergic encephalomyelitis (EAE)

Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1-but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats

Cyclosporin A treatment of an induced attack in a chronic relapsing model of experimental allergic encephalomyelitis

Histopathological characterization of magnetic resonance imaging-detectable white matter lesions in a primate model of multiple sclerosis. A correlative study in the experimental autoimmune encephalomyelítis model in common marmosets (Callithrix jacchus)

Neuropathic pain in animal models of nervous system autoimmune diseases

Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants

A comparative study of experimental allergic neuritis in rabbit, guinea-pig and mouse

New methods for multiple sclerosis drug discovery

Acute Graft Versus Host Disease (GVHD) in Rats

Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of auto-immune disorders and reactions leading to transplantation rejection

Effects of leflunomide on immune responses and models of inflammation

The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation

Pathophysiology, prevention, and treatment of acute graft-versushost disease

A lymph node weight assay for the graft-versus-host activity of rat lymphoid cells

Antibodies to a transfer RNA-associated protein in a murine model of chronic graft versus host disease

Graft versus host disease: new insights into A 2A receptor agonist therapy

Limitation of Hu-PBL-scid mouse model in direct application to immunotoxicity assessment

Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent

Novel regulatory therapies for prevention of Graftversus-host disease

Transfer of a functional human immune system to mice with severe combined immunodeficiency

Prevention of acute graft versus host disease (GVHD) in rats by the immunomodulating drug leflunomide

Graft-versus-host disease after Brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK 506

Benzimidazoisoquinolines: a new class of rapidly metabolized aryl hydrocarbon receptor (AhR) ligands that induce AhR-dependent tregs and prevent murine graft-versus-host disease

Bone marrow transplantation in the rat. I. Histologic correlation and quantification of cellular infiltrates in acute graft-versus-host disease

Prolongation of allogenetic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative

The new immunosuppressants, the malononitrilamides MNA 279 and MNA 715, inhibit various graft-vs.-host diseases (GvHD) in rodents

A77-1726, leflunomide's active metabolite, inhibits in vivo lymphoproliferation in the popliteal lymph node assay

Prevention of graft-versus-host-disease by RS-61443 in two different rodent models

Path to clinical transplantation tolerance and prevention of graft versus host disease

Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats

Elimination of acute GVHD and prolongation of rat pancreas allograft survival with DST, cyclosporine, and spleen transplantation

Effects of trichostatin A in a rat model of acute graft-versus-host disease after liver transplantation

Rapamycin and Tacrolimus differentially modulate acute graft-versushost disease in rats after liver transplantation

Animal models of graft-versus-host disease

Animal models of skin disease for drug discovery

Development of autoimmunity in MRL/lpr mice and the effect of drugs on this murine disease

Leflunomide (HWA 486): a novel immunorestoring drug

Assessment of the translational value of mouse lupus models using clinically relevant biomarkers

Polyarthritis in MRL-1pr/1pr mice: mouse type II collagen is antigenic, but not arthritogenic

The effects of CP 17193, an immunosuppressive pyrazoloquinoline, on the development of spontaneous lupus disease in NZBW F 1 hybrid mice

Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases

Periocular inflammation in mice with experimental systemic lupus erythematodes. A new experimental blepharitis and its modulation

Spontaneous autoimmune skin lesions of MRL/n mice: autoimmune disease-prone genetic background in relation to Fas-defect MRL/lpr mice

A systemic lupus erythematodes (SLE)-like disease in mice induced by abnormal T-and B-cell cooperation. Preferential formation of antibodies characteristic of SEL

Cyclosporine A and cyclosporine G enhance IgG rheumatoid factor production in MRL/Ipr mice

Involvement of macrophages and dendritic cells in synovial inflammation of collagen induced arthritis in DBA/1 mice and spontaneous arthritis in MRL/Lpr mice

Neuropsychiatric systemic lupus erythematosus and cognitive dysfunction: the MRL/lpr mouse strain as a model

Spontaneous development of pancreatitis in the MRL/Mp strain of mice in autoimmune mechanism

Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist: a role for the endogenous molecule?

T cells as treatment targets in systemic lupus erythematosus

Peptidylarginine deaminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice

MRL/MP-lrp/Lrp mouse as a model of immuneinduced sensorineural hearing loss

Treatment with Anti-Interleukin 23 Antibody Ameliorates Disease in Lupus-Prone Mice

Effects of prolonged treatment with memantine in the MRL model of central nervous system lupus

Small molecules in the treatment of systemic lupus erythematosus

Reducing FLI1 levels in the MRL/lpr lupus mouse model impacts T cell function by modulating glycosphingolipid metabolism

Serum amyloid P component and autoimmune parameters in the assessment of arthritis in MRL/lpr/lpr mice

Mouse models of systemic lupus erythematosus reveal a complex pathogenesis

Preclinical studies with 15-deoxyspergualin in various animal models for autoimmune diseases

Immunoregulation of murine SLE-like diseases by interleukin-4-receptor

The new immunosuppressants, the malononitrilamides MNA 279 and MNA 715, inhibit various graft-vs.-host diseases (GvHD) in rodents

Over-expression of Epstein-Barr virus-induced gene 3 protein (EIB3) in MRL/lpr mice suppresses their lupus nephritis by activating regulatory T cells

Androgen stimulation of lacrimal gland function in mouse models of Sjögren's syndrome

Etiopathogenesis of murine SLE

Impact of gender on exocrine gland inflammation in mouse models of Sjögren's syndrome

Vom Saal FS (1996) Effects of altered prenatal hormonal environment on expression of autoimmune disease in NZB/NZW mice

Diagnosis and early detection of CNS-SLE in MRL/lpr mice using peptide microarrays

Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease

Use of complementary peptides and their antibodies in B-cell-mediated autoimmune disease: prevention of autoimmune myasthenia gravis with a peptide vaccine

Thymus changes in experimentally induced myasthenia gravis

Treatment of experimental myasthenia gravis with cyclosporin A

Neuromuscular disorders: troponin activator improves muscle function

Increases in helper inducer T cells and activated T cells in HTLV-1 associated myelopathy

Recombinant human acetylcholine receptor αsubunit induces chronic experimental autoimmune myasthenia gravis

Induction of suppressor cells specific for AChR in experimental autoimmune myasthenia gravis

Properties of suppressor cells induced to acetylcholine receptor using cyclosporin A

Prevention of acute graft versus host disease (GVHD) in rats by the immunomodulating drug leflunomide

Measurement of acetylcholine receptors and anti-receptor antibodies by ELISA

Deficits in endogenous adenosine formation by ecto-5 0 -nucleotidase/CD73 impair neuromuscular transmission and immune competence in experimental autoimmune myasthenia gravis

Observations of the natural history of myasthenia gravis and effect of thymectomy

How clinical trials of myasthenia gravis can inform pre-clinical drug development

Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases

The effect of prolonged propranolol administration on myocardial transmural capillary density in young rabbits

Suppression of natural xenophile antibodies with the novel immunosuppressive drug leflunomide

Principles and methods for the morphometric study of the lung and other organs

Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine

Cyclosporin A induces long-term unresponsiveness in mercuric chloride-induced autoimmune glomerulonephritis

Effect of cyclosporin A on mercury-induced autoimmune glomerulonephritis in the Brown Norway rat

Effect of cyclosporin on active Heymann nephritis

Experimental crescentic glomerulonephritis: a new bicongenic rat model

Effect of the immunosuppressive agent, cyclosporin, on experimental immune complex glomerulonephritis in rats

Effect of cyclosporin A on autoimmune tubulointerstitial nephritis in the brown Norway rat

The effect of cyclosporin A on the interstitial mononuclear cell infiltration and the induction of Heymann's nephritis

Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspension

Crescentic type nephritis induced by anti-glomerular basement membrane (GMB) serum in rats

Cyclosporin reduces proteinuria in rats with aminonucleoside nephrosis

Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat

Single and combined effects of the vitamin D analogue KH1060 and cyclosporin A on mercuric-chloride-induced autoimmune disease in the BN rat

Immunocytochemical and biochemical characterization of the Heymann nephritis antigenic complex in rat L2 yolk sac cells

Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats

Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement antibody in rats

Cyclosporin A in the prevention and treatment of experimental autoimmune glomerulonephritis in the brown Norway rat

Preclinical studies with 15-deoxyspergualin in various animal models for autoimmune diseases

Isolation and properties of the soluble antigen specific for the production of nephrotoxic glomerulonephritis. I. Immunopathological demonstration of the complete antigenicity of the soluble antigen

Effects of cyclosporin A on the development of immune-mediated interstitial nephritis

A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis

Single application of low dose mycophenolate mofetil-OX7-immunoliposomes ameliorates experimental mesangial proliferative glomerulonephritis

Antiproteinuric effect of pirfenidone in a rat model of anti-glomerular basement membrane glomerulonephritis

P2X 7 deficiency attenuates renal injury in experimental glomerulonephritis

Cyclosporin A inhibits autoimmune experimental tubulointerstitial nephritis

Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats

Effect of cyclosporin A on antibody-induced experimental glomerulonephritis

T lymphocyte participation in antibody-induced experimental glomerulonephritis

Nephritogenic antibody mechanisms involving antigens within the glomerulus

Cyclosporin A and anti-glomerular basement membrane antibody glomerulonephritis in rats

Inhibition of Allogenic Transplant Rejection Adams DH

Rapamycin in a renal transplant model

Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection

Regulatory B cells and tolerance in transplantation: from animal models to human

Leflunomide therapy following penetrating keratoplasty in the rat

Cardiac transplantation in the rat

Improved tracheal allograft viability in immunosuppressed rats

Reevaluation of total-lymphoid irradiation and cyclosporine therapy in the Syrian hamster-to-Lewis rat cardiac xenograft model

New rapid technique for renal transplantation in the rat

Evaluation of cyclosporine, mycophenolate mofetil, and brequinar sodium combination therapy on hamsterto-rat cardiac xenotransplantation

Immuno-modulatory role of indoleamine 2,3-dioxygenase in allogeneic islet and skin transplantation

Cyclosporin and anti-interleukin 2 receptor monoclonal antibody therapy suppress accelerated rejection of rat cardiac allografts through different effector mechanisms

Prolonged survival of rat cardiac allografts by donor pretreatment with methotrexate

Immunosuppressive effects of FK 506 in rat lung transplantation

Allogenic transplantation of fetal rat intestine: anastomosis to the normal bowel of the host

Limitation of Hu-PBL-scid mouse model in direct application to immunotoxicity assessment

The adaptive ability of transplanted rat small intestine

A new rat infection-heart transplant model: effect of infection on graft survival studies

Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent

Morphological and immunological analysis of rats with long-term-surviving limb allografts induced by a short course of FK 506 or cyclosporine

Induction of graft-versus-host disease and rejection by sensitized small bowel allografts

An improved technique of renal transplantation in the rat

Experimental orthotopic transplantation of vascularized skeletal allografts: functional assessment and long-term survival

Immunosuppressant combinations in primate cardiac xenografts

Chronic rejection of rat aortic allograft. II. Administration of cyclosporin induces accelerated allograft arteriosclerosis

The outcome of neurovascularized allogenic muscle transplantation under immunosuppression with cyclosporine

Graft-versus-host disease after Brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK 506

Therapeutic activity of deoxyspergualin in comparison with cyclosporin A, and its combined use with cyclosporin A and prednisolone in highly allogeneic skin transplantation in the rat

Faulds D (1993) Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation

Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs

Synergistic activity of malononitrilamides with cyclosporine to control and reverse xenograft rejection

Prolongation of allogenetic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative

Mouse models of graftversus-host disease: advances and limitations

Vascular transplantation of Syrian hamster heart into Lewis rat: effect of brequinar, cyclosporine, cobra venom factor, and splenectomy

Prevention of graft-versus-host-disease by RS-61443 in two different rodent models

The inhibitor cytokine interleukin-1 receptor antagonist synergistically augments cyclosporine immunosuppression in a rat cardiac allograft model

The effect of combined treatment with total lymphoid irradiation, cyclosporin A, and anti-CD4 monoclonal antibodies in a hamster-torat heart transplantation model

Influence of liver transplantation and cyclosporin on bile secretionan experimental study in the rat

Kidney transplantation between congenic versus standard inbred strains of rats. I. The significance of H-1 and non-H-I gene differences

Suppression of natural xenophile antibodies with the novel immunomodulating drug leflunomide

Althaus U (1993) Magnetic resonance spectroscopy for assessing myocardial rejection in the transplanted rat heart

Immunosuppressive effects of leflunomide in a cardiac allograft model

Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine

Cytidine potentiates the inhibitory effect of brequinar sodium on xeno-MLR, antibody production, and concordant hamster to rat cardiac xenograft survival

Immune function in transplanted small intestine

Leflunomide: a promising immunosuppressant in transplantation

Electrophysiologic evaluation of peripheral nerve regeneration through allografts immunosuppressed with cyclosporin

Synergic silencing of costimulatory molecules prevents cardiac allograft rejection

 Murata et al. (2000) described a radioreceptorbinding assay for quantitative measurement of sphingosine 1-phosphate. 

 Patterson GA (1993) Improved tracheal allograft viability in immunosuppressed rats. Ann Thorac Surg 55:131-134 de Masi R, Alqaisi M, Araneda D, Nifong W, Thomas J, Gross U, Swanson M, Thomas F (1990) Reevaluation of total-lymphoid irradiation and cyclosporine therapy in the Syrian hamster-to-Lewis rat cardiac xenograft model.